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Óxido de zinco, poliuretano, ibuprofeno, sistemas de libertação de fármacos  
 
Para projectar um sistema de entrega de fármacos, em que se pretende 
armazenar uma grande quantidade de fármaco a ser libertada durante um 
período de tempo longo, é vantajoso recorrer a nanoestruturas com elevada 
área específica para o carregamento do fármaco por processos adsortivos. 
Além disso, a combinação de transportadores nanoestruturados com materiais 
poliméricos, formando sistemas compósitos para a entrega de fármacos pode 
proporcionar o controlo de certos parâmetros associados à  libertação do 
fármaco. Entre as várias combinações possíveis, o óxido de zinco (ZnO) e o 
poliuretano (PU) oferecem um particular interesse dado ser possível preparar 
ZnO nanoestruturado e o PU ser um polímero com reconhecida aptidão para 
aplicações médicas. 
 
Neste trabalho, estudaram-se vários aspectos do processo de libertação de 
um fármaco modelo (o ibuprofeno) a partir de nanoestruturas de óxido de zinco 
e de compositos ZnO/PU. Em particular, estudaram-se os efeitos da variação 
da carga do fármaco usando soluções etanólicas com diferentes 
concentrações do fármaco,i.e. 1, 2, 10, e 20 mg de ibuprofeno / mL de etanol, 
tendo-se demonstrado que por esta via se pode controlar a carga do fármaco , 
o que é importante para personalização da dose em sistemas de entrega de 
fármacos. Além disso, a importância dos procedimentos de lavagem das 
nanoestruturas após carregamento do fármaco foi também avaliada, 
concluindo-se que tais procedimentos condicionam a carga de fármaco por 
remoção das camadas de fármaco fracamente adsorvidas. Estudou-se 
também a libertação de ibuprofeno a partir das nanoestruturas de óxido de 
zinco puro e dos compositos ZnO/PU, medindo a variação no tempo da 
quantidade de fármaco libertada em solução tampão de fosfato. Os perfis de 
libertação do fármaco aliados às imagens de microscopia electrónica (SEM) 
dos materiais obtidas no fim de diferentes períodos de tempo de libertação são 
usados neste trabalho para discutir os mecanismos de libertação do fármaco e 
avaliar a sua relacção com a degradação do material em análise. 
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For the design of drug delivery systems, in which a large amount of drug 
should be stored and released over a sustained period of time, utilization of 
nanostructures is frequently advantageous as their high specific surface areas 
are beneficial for adsorptive drug loading. Additionally, the use of 
nanostructured drug carriers in concert with polymeric materials in composite 
drug delivery systems affords control over the drug release characteristics. 
While many combinations of materials can be imagined, the use of zinc-oxide 
and poly(urethane) is of particular interest in that nanostructures based on the 
former are easily producible and the latter is already an established material in 
biomedical applications. 
 
In this investigation, various aspects of the drug delivery properties were 
examined. In particular, the effects of altering the amount of drug loaded (by 
loading in solutions of 1, 2, 10, and 20 mg ibuprofen/mL ethanol) were studied 
and it was demonstrated that the amount of drug loaded can be controlled, 
which is important for customizing dosages in drug delivery systems. 
Additionally, the role of a washing procedure after loading the nanoparticles 
was examined in order to show that these procedures influence the drug 
loading by removal of loosely bound layers of drug. 
 
In completion of this study, the release of ibuprofen from both pure zinc oxide 
nanoparticles and the composites with poly(urethane) was investigated by 
tracking the concentration of drug present in a phosphate buffered saline 
solution containing the drug carrier with respect to time. In order better 
understand the mechanisms of drug release and analyze the degradation 
processes of the drug carrier, SEM images were produced for the samples at 
various times during the drug release process. 
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1. Introduction and Objectives 
 
 
1.1. Motivation 
 
 
With the advances in modern medicine and associated increases in quality of life as well as 
life expectancy, a further expansion of the paradigm for common treatment practices is 
necessary. In the case of hard tissue engineering, post operation drug-delivery is integral to 
recovery and rehabilitation. For this purpose, much research is focused on the topics of 
targeted and sustained drug delivery systems (SDDs), which can locally and consistently 
administer a drug to a desired location within the body over the course of an extended time 
period. Unfortunately, modern practices often fall short in achieving the therapeutic goals 
set out for drug treatment. Namely, conventional systems may not effectively target the 
desired site and, if this is indeed the case, the delivery is frequently characterized by a fast, 
burst-type drug release [1]. Addressing these two problems is the heart of current research 
trends in drug delivery systems. 
 
While many drug delivery systems (DDSs) can be envisioned, the focus of this thesis will be 
on ceramic nanostructured particles and composite materials comprising said 
nanostructured particles within a polymer matrix. Specifically, the material system of zinc 
oxide/poly(urethane) is the material  of interest. Each component has established 
application in biomedicine and preliminary studies on the composite system based on 
embedment of zinc oxide nanoparticles in a polyurethane matrix offer promising results [2].  
 
In studies on drug delivery systems, the unfortunate reality is the non-standardized 
methodology in sample preparation and experimental design. Naturally, the synthesis 
procedures must vary for the fabrication of an array of materials and sample types. 
However, significant ambiguity lies in the steps taken with the resulting drug delivery 
materials. For example, a common technique for loading the model drug into the DDS 
prescribes suspending the DDS in a drug-containing solution and allowing it to soak for a 
specified duration. Following collection of the powder, however, some authors report 
washing the DDS, often under the high forces of an ultracentrifuge. While such minor 
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differences in experimental procedure may seem insignificant, altering the initial state of the 
DDS before performing drug release experiments can complicate comparisons between 
different systems. 
 
 
1.2. Objectives 
 
 
While previous works have focused on the characterization and biocompatibility of the 
ZnO/PU nanostructured, composite DDSs, as well as on the various influences of 
alternative synthesis routes [2,3], the objective of this study will be to more specifically 
explore the drug release properties of both the nanostructured zinc oxide as well as the 
composite systems. Namely, investigations on the effect of the drug-loading environment 
will take place, where the concentration of drug in the solution will be varied in order to 
determine the extent to which the drug-loading amount can be controlled. Secondly, the 
effect of washing the nanostructured particles post-loading will be investigated in order to 
see if there exists some merit in this procedural step frequently reported in literature. 
Thirdly, drug release studies will be performed on composite samples of different weight 
ratios (relative amounts of ZnO and PU) in order to explore the effect the polymer plays in 
the drug release mechanics of the system as a whole. Finally, mathematical modeling of 
the data will be performed in an attempt to draw connections between the various release 
studies. For this, proposed equations commonly found in literature will be used.  
 
 
1.3. Thesis Structure 
 
 
This thesis will continue with a review of the state-of-affairs in the literature regarding DDSs 
in order to develop a background in the topic. Following will be an overview of the 
experimental procedures for material synthesis, characterization, and drug release 
experiments, after which the experimental data will be presented as well as a discussion of 
the results. Finally, a review of the main points will be given in the conclusion along with 
suggestions for future work. 
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2. Literature Review 
 
 
2.1. Drug Delivery Systems 
 
 
At its root, the concept of drug delivery is rather simple in that the end goal is simply to 
introduce a drug to the body in order to obtain the desired effects from the drug. However, 
the routes taken to achieve this goal differ greatly in both methodology as well as 
complexity. For example, orally administering a drug encapsulated in a pill is quite simple 
in comparison to the creative techniques envisioned for targeted drug delivery. One can 
easily imagine the advantages of targeted drug delivery, especially for the archetypical 
example of chemotherapy-based cancer treatments. With targeted drug delivery, the drug 
would be administered solely to the desired location, reducing the negative side effects 
associated with a general, non-targeted drug delivery. However, the ease of use for the 
delivery of drugs through methods such as inhalation, ingestion, or injection should not be 
overlooked.  
 
 
Figure 1: Comparison of controlled drug release with conventional drug administration 
 
As can be seen in figure 1, problems arise when little control is provided for the drug 
release. In the two extreme cases, either the drug concentration surpasses the toxic limit 
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in order to achieve a prolonged release or the drug concentration remains above the 
therapeutic threshold for only a short amount of time in order to ensure that the drug 
concentration does not surpass the toxic limit. These lines correspond to non-controlled 
drug release, such as would occur through oral or general administration of a drug—non-
targeted drug delivery systems. The ideal case, falling in the middle of the therapeutic 
threshold and toxic limit, is given for a controlled release system where the drug 
concentration within the body can be maintained between the two limits for an extended 
duration. 
 
In terms of targeted drug delivery, the range of techniques also varies quite drastically. 
While the group’s interest lies in zinc oxide-based nanostructures and their associated 
composites, techniques such as the use of liposomes, fullerenes, or carbon nanotubes 
have been proposed [4]. In these examples, the drugs are loaded into fabricated vesicles, 
which serve to transport a drug or other agent of interest in a cage-like structure. While 
fullerenes and carbon nanotubes can be categorized as carbon nanostructures, the basis 
of the liposome structure is a bilayer of lipids, small organic molecules typically associated 
with ampiphilicity. Through functionalization of these vessels with various ligands, the 
carrier structure can target specific cells for drug delivery. As the targeting nature of the 
nanocarriers allows a reduction in the adverse side effects expected for small molecule 
drugs such as the platinates, camptothecins, or adriamycins (commonly used cancer 
treatments), much research is focused on such delivery systems [5]. In this case, the drug 
delivery system functions by forcing the drug movement throughout the body to a specific 
location after administering the system in a general manner. The drug release can then 
commence once the system arrives at the site of interest. 
 
However, while these notable examples indeed offer promising application in the realm of 
targeted drug delivery, they would first be generally introduced into the body and the 
targeting would then follow based on the chemistry of the carriers. Alternatively, the 
targeting aspect of drug delivery could include physical administration of the drug to the 
desired site. Indeed, this is how the delivery would take place for the ZnO/PU system, with 
the drug loaded into a composite material applied directly to the target site as a part of a 
surgical procedure, for example. 
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In the case where the targeted delivery is completed by direct application of the drug 
carrier to the target site, developing a system in which the drug delivery can continue for 
long durations is also desirable. It is therefore imperative to improve the capabilities of the 
delivery systems to promote sustained drug release in addition to simply developing the 
targeting in general. More specifically, the goal is to enable continuous and consistent 
delivery of the drug of interest. Or rather, the goal is to be able to control the release of the 
drug in order to fine-tune both the dosage and duration of drug delivery so that the DDS 
can be useful for several applications. 
 
The heading of “targeted drug delivery systems” can thus be split into two categories, 
depending on the method by which the targeting occurs: “smart” carriers, and direct 
application devices. The term “smart carriers” describes devices, typically of a nanoscale, 
which respond to some external signal in order to deliver the drug to the target site. This 
means that, while the system could be administered generally, the drug activity would be 
limited to the area of interest. For example, a carrier could be functionalized so that the 
drug release would be triggered on pH changes. As tumorous cancer cells exhibit a lower 
pH than healthy cells, the delivery of antitumoral drugs could be restricted to tumorous 
cells through the use of a “smart” delivery system. Further external triggers could include 
application of a magnetic field, ultrasound, electric field, temperature change, light, or 
mechanical forces [6]. For the second category, the direct application of a drug delivery 
system describes a method for containing the drug activity simply by limiting the location 
of the drug delivery device in the body. Such would be the case for implant materials, 
transdermal patches, or wound dressings, among others [7]. 
 
As previously mentioned, in terms of post-operation therapy, maintaining a continuous 
pharmaceutical level above a certain minimum concentration is necessary in order to 
ensure the most effective treatment. For example, with antibacterial treatment, a minimum 
inhibitory concentration (MIC) must be maintained, which is analogous to the previously 
introduced term “therapeutic threshold”; below this value, the drug is no longer effective. 
Furthermore, this concentration must be maintained at the specific target site. With non-
targeted delivery, a high concentration of drug will be present throughout the entire body, 
resulting in negative side effects due to the widespread presence of drug, as occurs when 
the drug concentration surpasses the toxic limit.  
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To highlight the efficacy of targeted, sustained delivery systems, it is useful to compare 
the drug concentration profiles as shown in figure 2. Additionally, this type of graphic will 
serve as the basis for comparison of the various drug delivery systems investigated in the 
literature review. While the graphic specifies release profiles for proteins, these curves are 
representative for any type of release. Furthermore, these hand-drawn curves are simply 
intended to serve as examples for the various types of release profiles; they are not 
associated with any particular set of experimental data, which is also valid for figure 1. 
 
 
Figure 2: Types of delivery profiles, adapted from [8] 
Red: continuous delivery, Yellow: delayed delivery, Blue: pulse-like delivery 
 
In general, continuous administration of the drug can be ensured by repeated doses, 
characterized by a pulse-like profile of the drug concentration within the body, shown as 
the blue line in the figure. An extension of this profile as seen in the figure would describe 
the familiar example of “take two pills, twice daily” associated with a doctor’s instructions 
for prescribed medication. However, for cases where the drug is administered directly to 
the targeted site, as would occur by introducing the drug delivery system during a surgery, 
repeated dosage is not a viable solution to ensure continuous drug availability; once the 
concentration reduces below the MIC, it is no longer realistically possible to reintroduce delivery of GFs) and to elicit the desired biological responses
within the scaffold relies on the use of nucleic acid-releasing
systems. In principle, nucleic acids containing a sequence
encoding for specific proteins can be introduced into target
cells, which are thus prompted to produce the desired proteins.
Alternatively, oligonucleotides can be used to return abnormal
gene expression to a certain state in antisense and interference
therapies based on silencing RNA [77]. In this way, cells
genetically induced to secrete proteins may act as point-source
DS, allowing a prolonged and more specific effect.
For a successful gene-mediated TE approach, synthetic
oligopeptides containing the adhesion site of fibronectin (the
RGD sequence) have been used [36,78]. The nanoscale
distribution of the oligopeptides chemically coupled to adhesion
substrates was found to mediate the efficiency of gene delivery
[36]. Gene expression levels increase with increasing oligopep-
tide density (i.e. stiffness of adhesion), which enhances the
ability of cells to internalize plasmid DNA. The use of
biomaterial-based devices modified with specific cell-adhesion
molecules can maximize the population of stimulated cells [78].
In perspective, coupling oligopeptides containing the RGD
sequence to protein-loaded DS may improve the cellular
response to GFs by exposing cells to genes according to a
predetermined scheme, thus activating the tissue-inductive cell
machinery.
Synthetic gene-activated matrices, loaded with plasmid, may
also play a prominent role as cell-activating scaffolds for TE.
Time-controlled release of the plasmid encoding for tissue-
inductive PDGF from porous PLGA matrices lead to matrix
deposition and vascular bed formation [62]. Similarly, the
dispersion of plasmid DNA encoding for both angiogenic and
osteogenic factors within PLGA scaffolds resulted in a gene-
activated cell recruitment from peripheral tissue promoting
osteogenesis [79]. Bioengineered tissues secrete recombinant
proteins and act as long-term DS when implanted in vivo.
Myoblasts retrovirally transduced to locally secrete recombi-
nant VEGF induced the regrowth of a functional capillary bed
in the bulk of a bioengineered tissue substrate and in the
adjacent muscle ischemic tissue [80]. More recently, genetically
activated rabbit bone marrow stromal cells engineered to
express BMP-4 in a porous PCL scaffold effectively promoted
new bone tissue formation [81].
The concept of gene-mediated protein expression has been
put forward by immobilizing DNA at the pericellular level, thus
triggering molecular signal broadcasting from cells, probably
due to high local concentration of DNA in the cellular niche
[82]. Combining GF delivery with covalent attachment of DNA
able to dictate protein release from the cells may improve tissue
response. Actually, dual delivery of BMP-2 and a plasmid
encoding the same protein may induce a feedback mechanism
by which the transcription efficacy of the plasmid was further
increased, thus opening the way to possible pathways eluding
viral gene transfer [83].
The results of combined GF and gene delivery suggest the
opportunity of a sequential release of multiple signaling
molecules, allowing the recapitulation of tissue formation
steps at predetermined time intervals and/or after induction
times. However, the synchronization between the intracellular
transport of gene material and the activation of protein
expression by cells is still far from being optimized. Current
understanding suggests that the properties of the pericellular
space, the delivery method and the biomolecule structure must
Fig. 2. Protein release from non-biodegradable (A), soluble/biodegradable (B) and pulsatile (C) delivery systems. Continuous, delayed and pulse-like delivery may be
achieved with non-biod gr dable and solubl /biodegradable delivery systems (D). On–off delivery (single or multi-pulses) may be achieved with pulsatile (pre-
programmed or triggered) delivery systems (E).
235M. Biondi et al. / Advanced Drug Delivery Reviews 60 (2008) 229–242
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the drug. Additionally, as was seen in figure 1, problems often arise when the drug 
concentrations exceed the toxic limit. When this repeatedly occurs problems may arise 
regarding drug side effects. To address this problem, the drug release should be 
sustained for the treatment duration. A release profile for a sustained release can be seen 
as the red line in the figure 2. This type of release profile is described by an initial steep 
increase in concentration followed by a plateau at a maximum concentration. Additionally, 
for a third situation, the yellow line in figure 2 displays the profile for a delayed release, 
which is similar to the continuous delivery, but the initial step is offset by a delay time. 
 
Although the reported delivery systems (these will be discussed in following sections) 
generally displayed release profiles coinciding with the continuous release curve, the 
differences in time-scale are what necessitate the engineering of advanced delivery 
systems. Namely, the optimal release curve requires maintenance of the plateau 
concentration for the duration of treatment. It is of little use if the continuous delivery is 
concluded after only a few hours when the ideal therapy involves several days of drug 
administration. Additionally, a consistent delivery is also desired for the optimal release 
profile. Perhaps the greatest challenging to designing effective delivery systems is to 
reduce the typical ‘initial burst’ seen by a surge of drug released within a short amount of 
time followed by a reduced release rate. Finally, the drug loading capacity for a delivery 
system must be considered. This property simply refers to the amount of drug that can be 
stored in a delivery system and is typically given as a weight ratio between the drug 
loaded and the carrier itself.  
 
 
2.1.1 Use of Nanoparticles in a Delivery System 
 
 
It should now be apparent that the crux of designing the delivery systems lies in enabling 
a continuous release for a sustained period and maximizing the drug loading capacity. For 
the proposed system of ZnO/PU, or ceramic/polymer composites in general, the main 
mechanism for the drug-uptake relies on the adsorption of the drug molecules onto the 
surface of porous, inorganic nanoparticles. Because of this, a key parameter will be the 
surface area to volume ratio of the particles, which can be maximized by a reduction in the 
particle size.  
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However, a reduction in size of a material can also be associated with a change in the 
material properties, such as a change in the absorbance spectrum for gold nanoparticles 
[9]. With this in mind, the toxicity of the inorganic nanoparticles must be considered, as the 
toxicological properties of the inorganic nanoparticles may not necessarily correlate with 
those of the bulk material. Additionally, the toxicological properties of nanoparticles 
changes upon incorporation into a composite material; toxicity is important for isolated 
nanoparticles.  
 
 
2.1.2 Use of Polymers in a Nanocomposite Delivery System 
 
 
To address the challenge of achieving a sustained drug release, novel techniques must be 
employed in order to optimize the release profile. A promising method relies on the use of 
polymeric materials in a nanocomposite with inorganic nanoparticles. In this way, the 
polymeric matrix could serve as a diffusion barrier for the drugs, increasing the time scale 
of the drug release and suppressing the initial burst. Additionally, the drugs could be 
stored in a biodegradable polymer, and the drug release would coincide with the 
biodegradation of the polymeric material. It is one of the goals for the study of the ZnO/PU 
system to determine the role that the poly(urethane) plays in terms of drug loading and 
release. Appropriate results from literature regarding the use of polymers in drug delivery 
systems will be discussed. 
 
 
2.2 Drugs of Interest in Drug Delivery Systems 
 
 
Naturally, the goal of a delivery system is to introduce a specific chemical into the body in 
a controlled manner. Drugs of particular interest for tissue engineering include, but are not 
limited to, proteins, growth factors, antibiotics, anti-inflammatory, and anticancer drugs. 
With the introduction of these compounds to the body, recovery may be facilitated through 
promotion of tissue regeneration, prevention of infections, and alleviation of pain caused 
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by the procedure. Of course, tissue engineering is not the sole application envisioned for 
drug delivery systems. For example, administration of drugs through the skin via fiber 
mats in a transdermal patch serves as an additional use for drug delivery systems [10].  
 
However, with the assortment of attractive drugs for various therapeutic applications, it 
must not be forgotten that their different properties determine their respective loading and 
release behavior in a delivery system; the chemistry of the drug molecule dictates the 
kinetics of the delivery process, as well as the drug loading mechanisms and degradation 
of the loaded system. That is to say, an ideal delivery system tailored to one species may 
not (and likely will not) necessary prove effective for a second drug. Differences in 
molecular structure (size, geometry, hydrophobicity, etc.) and electrostatic properties 
mean that each drug should be treated on a case-by-case basis. This must also be 
remembered when comparing the systems proposed in literature, as the standards set for 
gentamicin delivery systems differ from those for salicylic acid, for example.  
 
Fortunately a large number of studies have used ibuprofen as the model drug. Ibuprofen is 
an anti-inflammatory drug often taken to alleviate pain associated with rheumatoid arthritis 
as well as to treat mild aches associated with fever, headaches, or common cold [11]; it is 
of particular interest in this study due to its broad range of application, such as 
effectiveness in reducing post-operation swelling and associated pain for bone surgeries. 
The chemical structure of ibuprofen is presented below in figure 3, and the molecule is 
characterized by empirical formula of C13H18O2, a molecular weight of 206.26, and a 
melting point between 75-77°C [12]. 
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Figure 3:  Molecular Structure of Ibuprofen, adapted from [13] 
 
In terms of loading ibuprofen, it is important to note the polarity of the molecule, as this 
property may dictate its ability to adsorb onto certain drug delivery systems. For example, 
the –COOH groups of ibuprofen tend to form electrostatic bonds with Ca2+ species in 
calcium silicate hydrate based drug delivery systems [14]. Additionally, the size of the 
molecule can play a role where geometrical constraints are considered, as is the case for 
mesoporous drug carriers with channels of small diameters. These and other factors will 
be discussed in further detail with respect to particular delivery systems later in this report. 
 
Though ibuprofen is frequently used as a model drug in studies related to drug delivery, 
the array of other drug types should not be overlooked, as each has its place in modern 
medicine. In examples of bone replacement, delivery of antibiotics is commonly desired in 
order to prevent bone degradation due to periodontis or other related infections [15]. 
Additionally, the administration of growth factors and proteins can serve to promote growth 
of natural bone in order to slowly remodel a bone defect [16]. Naturally, the use for drugs 
extends well beyond tissue engineering, such as the use of antitumoral drugs in cancer 
treatment [4]. 
 
 
failed to establish if polymorphisms of CYP-2C9 or CYP-
2C19 are associated with liver disease.
There do not appear to be any differences in R(-)/S(?)
pharmacokinetics with sex in adults (Knights et al. 1995;
Walker and Carmody 1998) with the exception of the
volume of distribution VD/F being about twice that in adult
females compared with males (Walker and Carmody
1998). As noted later there are age differences in plasma
levels and kinetics of ibuprofen; elderly subjects have
slightly prolonged values of elimination half life for the
total drug concentrations (Albert and Gernaat 1984) or the
AUC for S(?) ibuprofen (Chen and Chen 1995).
Compromised liver metabolism in patients with mod-
erate to severe cirrhosis leads to prolongation of the t1/2 to
3.1 h and 3.4 h for R(-) and S(?) ibuprofen with evidence
of reduced metabolic inversion of the R(-) to S(?)
enantiomer (Li et al. 1993). Alcoholic liver disease also
prolongs the Tmax for the total Cp as well as the t1/2 (Albert
and Gernaat 1984). Elevation of the AUC for S(?)
ibuprofen and higher S(?)/R(-) ratios have been observed
in patients with a variety of chronic inflammatory diseases
who have impaired renal function (Chen and Chen 1995).
Surgical removal of wisdom teeth has been found to
cause substantial reduction in the serum concentrations of
both R(-) and S(?)-ibuprofen (by 2.6 and 3.5-fold,
respectively) with prolonged Tmax from approximately 1 h
to 4–6 h depending on the dose (Jamali and Kunz-Dober
1999). It was suggested that a number of stress-related
factors influencing GI functions could contribute to
reduced gastric absorption of ibuprofen (Jamali and Kunz-
Dober 1999). These observations are of particular thera-
peutic importance for they argue in favour of higher doses
of the drug for pre-emptive or post-operative surgery.
Phase II metabolism involves formation of phenolic and
acyl glucuronides (Rudy et al. 1991; Kepp et al. 1997;
Brocks and Jamali 1999; Graham and Hicks 2004) and a
minor route of conjugation with taurine which is stereo-
specific to the S(?) enantiomer because of formation from
Fig. 2 Oxidative metabolism of
ibuprofen. (From Graham and
Williams, 2004; reproduced
with permission of the
publishers, Taylor & Francis,
London)
Ibuprofen 279
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2.3 Factors that Influence Drug Release 
 
 
The drug release is influenced by many factors, especially those that relate to the 
adsorption properties of the system such as porosity of the drug carrier, chemical 
interactions between the drug and surface of the carrier, and the use of diffusion barriers 
such as polymer coatings. Several systems have been reviewed which allow analysis of 
these factors. Namely, inorganic DDSs based on calcium phosphate materials were of 
interest due to their prevalence in biomedical research and chemical similarity to natural 
bone inorganic phase; systems based on mesoporous silica (SiO2) are also of interest, as 
these oxide materials, when characterized by nanoscopic morphologies, could function 
similar to ZnO nanoparticles. 
 
 
2.3.1. Porosity of the Drug Delivery System 
 
 
The porosity of the DDS plays a large role in the drug release profile; furthermore, the 
pore morphology, including pore size, tortuosity, and interconnectivity also influence the 
drug release. When considering porosity, the pore scale is of importance, as the pore 
sizes may range from a few nanometers in the case of mesoporous silicates, to hundreds 
of microns for hydroxyapatite scaffolds.  
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Figure 4: SEM of a porous scaffold as produced by Palazzo et al. showing the microporosity on the 
walls of the macropores, adapted from [17] 
 
To begin, hydroxyapatite scaffolds offer attractive potential for applications in bone implant 
materials and drug delivery devices due to their structural similarities to the mineral phase 
of natural bone [17, 18]. A typical scaffold used as a DDS can be seen in figure 4, with the 
porous nature of the material clearly observable. It was found that variations in processing 
parameters affected the drug release profile. Namely, the type of drug loaded, the porosity 
of the scaffolds, and the amount of drug loaded were investigated. The respective drug 
release profiles are shown in figure 5. Beginning with the topmost graph, the influence of 
the type of drug is shown and the idea is reinforced that a delivery system optimized for 
one type of drug may not necessarily be the best system for a different drug. It can be 
seen that the release of ibuprofen is more complete, meaning that less residual drug 
remains in the delivery system after the drug release plateaus. For hydrocortisone, less 
than 80% of the drug releases, even after 300 minutes. Furthermore, the initial drug 
release is more evident in the case of hydrocortisone. Both of these results are due to the 
higher steric hindrance of hydrocortisone, which hinders the diffusion of the molecule 
through the porous network of the scaffold, resulting in the slower overall release seen by 
the incomplete drug release after 300 minutes. For the same reason, the drug tends to 
concentrate on outer macroporous walls, leading to the rapid initial burst release.  
 
A number of computational models of drug delivery
were developed, based on the main assumption that pure
diffusion occurs both in the porous matrix and the solvent
(water). Convective contribution to drug transport was not
considered and species conc ntration equation wa solve :
Bc
Bt
¼ div D grad cð Þ þ qc ¼ Dj2cþ qc ð1Þ
where c is the species mass concentration, D is the mass
diffusion coefficient for drug in the domain in which the
equation is solv d and qc is a sink/source term. An ffective
drug diffusivity was used in the porous matrix accounting
for its porosity.
A preliminary series of analysis included axial-symmet-
ric models with standard boundary conditions, as reported in
the literature [15]. Sink co d tion and finite solvent volume
condition were studied in these simulations. Perfect sink
simulations were carried out with zero concentration
i posed on th HA device walls as it was mmersed in an
infinite volume of fixed fluid. Perfect sink boundary
condition was then removed to make the model more
similar o usual experiments carried out in laboratories. This
(a) (b)
(c)
Fig. 3. SEM analysis: morphology of a 60% p rosity graft (a) and of a 40% p rosity graft (b). Microporosity in the macr pore wall (c).
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Fig. 4. Percentage mass release of Ibuprofen-lysine and Hydrocortisone Na-succinate from porous ceramic grafts with the same total porosity (60%) and with
the same drug load.
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Figure 5: Drug release profiles for hydroxyapatite scaffolds as prepared by Palazzo et al. From top to 
bottom: effect of drug type, effect of total porosity, and effect of amount of drug loaded, adapted from 
[17] 
 
A number of computational models of drug delivery
were developed, based on the main assumption that pure
diffusion occurs both in the porous matrix and the solvent
(water). Convective contribution to drug transport was not
considered and species concentration equation was solved:
Bc
Bt
¼ div D grad cð Þ þ qc ¼ Dj2cþ qc ð1Þ
where c is the species mass concentration, D is the mass
diffusion coefficient for drug in the domain in which the
equation is solved and qc is a sink/source term. An effective
drug diffusivity was used in the porous matrix accounting
for its porosity.
A preliminary series of analysis included axial-symmet-
ric models with standard boundary conditions, as reported in
the literature [15]. Sink condition and finite solvent volume
condition were studied in these simulations. Perfect sink
simulations were carried out with zero concentration
imposed on the HA device walls as it was immersed in an
infinite volume of fixed fluid. Perfect sink boundary
condition was then removed to make the model more
similar to usual experiments carried out in laboratories. This
(a) (b)
(c)
Fig. 3. SEM analysis: morphology of a 60% porosity graft (a) and of a 40% porosity graft (b). Microporosity in the macropore wall (c).
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Fig. 4. Percentage mass release of Ibuprofen-lysine and Hydrocortisone Na-succinate from porous ceramic grafts with the same total porosity (60%) and with
the same drug load.
B. Palazzo et al. / Materials Science and Engineering C 25 (2005) 207–213210
latter model was made of two sets, one representing the
porous matrix and one modelling a finite volume of liquid
solvent. In addition, simulations were carried out with
different initial conditions (drug loading) as well as matrix
properties (porosity, diffusivity).
Improved three-dimensional models were also developed
to take into account the effects of the solubility limit on drug
release. These models needed to develop Fortran subrou-
tines to be linked to the FIDAP solver based on a hypothesis
found in the literature [10]. In these simulations, drug
dissolved into water was modelled by means of the mass
source qc, whose value was computed time step by time step
so as to prevent drug concentration at the HA surface
exceeding drug solubility limit in water.
According to the above models, diffusion was the sole
phenomenon governing drug release process. Further com-
putational models were then developed including desorption
behaviour, too. Solute desorption from matrix walls is
governed by physical–chemical parameters depending on
matrix and drug nature. These effects were modelled through
a phenomenological correlation between the drug mass
dissolved in solution in each time step, its initial concen-
tration and the matrix porosity based on experimental data. In
particular, experimental data were fitted with the relationship:
c tð Þ ¼ eln cl$at ð2Þ
where c(t) is the instantaneous average drug concentration in
the solvent, cl is the asymptotic concentration in the solvent
(after an infinite time) and a is a control parameter in the
logarithmic interpolation of the experimental data. The drug
flux from the HA graft surfaces into the solvent (inside the
porous graft) was assumed to be generated by the phenom-
enological correlation (2) and described by means of the
source term qc in Eq. (1).
With regard to the FEM implementation, both porous and
fluid domains were discretized using 4-node, isoparametric,
quadrilateral elements in the preliminary axial-symmetric
models in order to generate a mapped mesh, also including
refined regions where higher species concentration gradients
were expected.
Mesh sensitivity analysis was performed based on
models exhibiting numbers of nodes in the range of 5151
to 10,011 for sink condition models and in the range of
20,301 to 39,621 for finite external fluid volume models.
The three-dimensional models accounting for the solubility
limit used 8-node hexahedral elements with node number
ranging from 103,727 to 124,357.
3. Results and discussion
Cylindrical hydroxyapatitic graft at two different degree
of porosity, 60% and 40% were prepared using starting
powders with 85% and 35% of crystallinity degree,
respectively. Previous experiments demonstrated that pow-
der samples with crystallinity degree of about 80% yield
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Fig. 5. Percentage mass release of Hydrocortisone Na-succinate from ceramics with different porosity (60 and 40%) and with the same drug load.
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macroporosity optimal for bone ingrowth [19]. Porosity
values were determined by a geometrical method. The
porosity determined by means of porosimeter resulted 8–
18% and 50–60% for microporosity and macroporosity,
respectively. The sum of micro and macroporosity results
lower than the total value determined by the geometrical
method due to the presence of small amount of closed
porosity. The shape and morphology of the ceramic graft are
shown in Fig. 2; the morphology of different porosity grafts
(60 and 40%) is compared in Fig. 3a and b, respectively. A
macroporosity up to 400 Am and a diffuse microporosity
ranging between 10 and 0.1 Am can be observed: Fig. 3c
shows the microporosity in the macropore wall. These
porous HA ceramics after implantation in vivo exhibited a
strong bonding to bone with pores contributing to a
mechanical interlock leading to a firm fixation of the
material with animal tissue. Details on biocompatibility
and bioactivity in vivo of the HA porous ceramics were
reported in a previous paper [8].
Ceramic grafts at high (60%) and low (40%) porosity
were loaded with different amounts of Ibuprofen-lysine and
Hydrocortisone Na-succinate. Drugs kinetics release was
experimentally evaluated as a function of drug steric
hindrance, drug loaded amount and device porosity and
contemporaneously studied by means of a computational
approach.
The effect of drug steric hindrance on release has been
studied. The data reported in Fig. 4 show the release of
Ibuprofen-lysine and Hydrocortisone Na-succinate from
porous ceramic grafts with the same percentage of total
porosity (60%) and with the same drug load.
The plots show how the more drug is sterically hindered,
the more initial drug release is stressed, because it tends to
concentrate itself on the external macroporous walls, with-
out reaching, through microporosity, the graft internal pores.
Nevertheless, after the first 40 min, Hydrocortisone Na-
succinate release kinetics results slower than Ibuprofen-
lysine one. This behaviour can be due to the difficulty for
the more sterically hindered molecules to move throughout
microporosity. TG-DTG put in evidence the interactions of
both drugs with the inorganic phase. The kinetics and the
amount of weight losses of Hydrocortisone Na-succinate
and Ibuprofen-lysine during the thermal treatment (from 25
8C up to 900 8C), lead to a different pattern dependent if
drug is free or loaded on the inorganic porous graft.
The effect of device porosity on drug release can be
evaluated from the curves reported in Fig. 5, which shows
the release of Hydrocortisone Na-succinate from ceramic
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In the middle graph can be seen the effect of porosity observed in the study. Note that the 
graphs were produced using hydrocortisone. Here, the initial burst is seen to be higher for 
the materials of lower porosity, as well as the overall faster release shown by the more 
complete drug release. In this case, the initial burst is also promoted by the higher 
concentration of drug on the external macropore walls. It follows that with a less porous 
scaffold, more of the drug must be concentrated on external walls and a higher burst type 
release will thus be observed. Indeed, this is the case. The effect of drug loading amount 
also plays on this same phenomenon. As more drug is loaded and the micropores are 
filled, the drug must adsorb to the walls of the macropores, resulting in the higher burst 
release observed for the sample loaded with more drug [17].  
 
The study of scaffolds can be extended to analyze the influence of nanopore size within 
the scaffolds themselves [18]. The initial burst release was seen to be particularly 
dependent on these pore sizes. Figure 6 shows the ibuprofen drug release profiles for two 
samples from another study where drug release properties of hydroxyapatite-based 
materials, Sp3 and Sp4, are investigated. These samples differed in their preparation by 
variation of microemulsion content, which translated to different pore morphologies in the 
final materials. More specifically, the sample Sp3 had smaller pores with an average 
diameter of 60 nm and a porosity of 54.7% while sample Sp4 had pores with an average 
diameter of 146.4 nm and a porosity of 64.6%. Furthermore, the tortuosity reported for the 
Sp3 samples was higher, meaning that the diffusion pathways inside the sample included 
more twists and turns. Shown by the black line in the figure, the data for Sp4 is presented 
in the curve showing the higher burst release, being steeper at times less than four hours. 
The first observation one may notice is that the role of porosity has the opposite effect as 
was observed by Palazzo. However, it must be remembered that the pores here are of a 
different size scale than the macroscopic pores of the previous data. Another important 
difference is that in the scaffolds prepared by Öner et al., the pores were more or less 
uniform. Therefore, with the larger pores, the diffusion of ibuprofen was much easier than 
for smaller pores. Because of this, the initial burst effect was more pronounced in the 
samples of higher porosity.  
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Figure 6: Drug release profiles for hydroxyapatite scaffolds as prepared by Öner et al. showing the 
effect of porosity, adapted from [18] 
 
The investigation of the effect of pore morphology on drug release is the focus of many 
studies on the use of mesoporous silicate-based DDSs. The typical silicate structures in 
the present discussion are characterized by having strongly ordered porous networks, with 
pore diameters less than 100 nm [19-22].  
 
In materials where the pore sizes are on a similar order of magnitude as the size of the 
drug molecule, diffusion and drug release properties are frequently limited simply by 
geometrical constraints. In MCM-41 synthesized with pore diameters of 2.5 nm, the 
ibuprofen molecules cannot overlap for efficient adsorption in the pore channels [22]. This 
effect can be seen in figure 7. However, for the MCM-41 sample with 3.6 nm pore 
diameters, the ibuprofen could efficiently pack on the pore surfaces. The relationship this 
has with the release profile can be seen in figure 8.  
 
coefficient obviously results in lower rate of release as would be
expected. The diffusion coefficients calculated for IBU
molecules within these tablets are presented in Table 3. The
experimental results showed a trend of decreasing Deff with
lowering temperature. Hence, lower temper ture restricted the
free movement of IBU molecules. These results suggest that the
diffusion of IBU molecules through the porous network can be
controlled by temperature.
It is well known that incre e in t mp rature results in an
increase in molecular diffusion rate. There is barrier to
diffusion created by neighboring atoms. This barrier should be
relocated in order to allow diffusion atoms to pass. Temperature
is a measure of molecular motion. Thus at mic vibrations
created by temperature assist to diffusion. Lin et al. [49] tested
drug delivery system involving diffusion of the drugs and
observed in significant increase in diffusion rate at 37 8C
compared to those obtained at 24 8C. It was reported that
release rate increased by a factor of 3, 2 and 5 for different
drugs.
4. Conclusion
The aim of this work was to elucidate the underlying drug
release mechanisms from HAP tablets, using IBU as model
drug. The effects of different formulations and processing
parameters on the resulting drug release kinetics in SBF and pH
7.4 were studied and the obtained results were analyzed using
adequate mathematical models in order to get further insight
into the underlying mass transport mechanisms. The micro-
emulsion content of the tablet was found to strongly affect the
underlying drug release mechanisms. Drug release from tablets
was primarily controlled by diffusion-controlled drug release
rate. The effective diffusion coefficient is depending on the
porosity and tortuosity of the porous tablets. The burst release
seen in the dissolution profiles was attributed to the presence of
drug on the surface of the tablet, while sustained release was
attributed principally to the location of drug within the pores.
The effects of the pore size of tablets prepared on the resulting
drug release kinetics could be quantitatively predicted using an
analytical solution of Fick’s second law of diffusion. This result
suggests the possibility of predicting the drug delivery from
HAP tablets in different ituations.
In summary, a simple one-step synthesis route for making a
porous hydroxyapatite tablets is proposed. This material
exhibits porous crystalline structure, which is suitable for drug
(IBU) r lease s a rug carrier. This system demonstrates a
potential application in the fields of drug delivery and disease
therapy based on its bioactive and porous properties.
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Figure 7: Effect of Pore diameter in mesoporous channels on the drug loading of MCM-41, adapted 
from [22] 
 
It can be seen from the release profiles that the drug release rate for the larger-pored 
samples is significantly faster. For the samples MCM-418(70%)-10(30%) and  
MCM-418(85%)-10(15%) the authors reported incomplete delivery even after three weeks, while 
the other two samples had completely released the ibuprofen after three days. TG data 
were taken after the drug loading to determine the weight percent of drug loaded, and the 
release rate was determined by observing when the total drug released compared to this 
value. Additionally, the total amount of drug release is higher for the MCM-4116 and  
MCM-4112 samples, due to the larger pore volume in the samples with a larger pore 
diameter. This follows from simple geometrical considerations. As various samples were 
synthesized by using different surfactants, it is possible to control the pore sizes by 
adjusting the ratios of surfactants. Furthermore, the pore volume and subsequent amount 
of drug loaded are also controlled by the surfactants used in synthesis. Therefore, the 
drug dosage and delivery rate can be engineered based on the synthesis procedure.   
 
for the inclusion of ibuprofen inside the channels seems
to be the hydrogen bond interaction between the ibu-
profen molecule and the silanol groups present in the
pore wall. If the pore diameter is much larger than the
ibuprofen molecule, as it happens for the samples ob-
tained from C16 and C12 surfactants, a close packing of
guest molecules takes place, lining the channels with a
‘‘rim’’ of densely packed molecules which reduces the
eﬀective pore size of the channels, but do not fully oc-
cupy the space available for N2 adsorption [1]. As the
pore size decreases below the threshold value, which
would be close to twice the eﬀective length of the ibu-
profen molecule, close packing of the guest molecules
along the pore wall is avoided by simple geometry con-
siderations. In this case, the pores are blocked for N2
adsorption, but nevertheless empty regions would exist
between the ibuprofen molecules that are present inside
the channels. In this way, the apparent volume occupied
by ibuprofen is higher than that expected from its
molecular size. Fig. 3 illustrates the packing model pre-
valent for the diﬀerent MCM-41 pore size. Nevertheless,
it should be indicated that current research points to the
presence of the ibuprofen as its dimer variety inside
the channel [14], although this fact should not aﬀect to
the drug disposition inside the pores mentioned above.
Fig. 4 displays the kinetics of ibuprofen liberation to
the SBF solution. Data for C16 and C12 materials with
a pore diameter of 3.6 and 3.3 nm respectively have been
included for comparative purposes. It can be observed in
the figure that the delivering rate decreases strongly as
the pore size varies from 3.6 to 2.5 nm. From the initial
portion of the plot the liberation rate can be estimated
to decrease from 24 mg/h for a pore size of 3.6 nm, to 5
mg/h for 2.5 nm. This fivefold decrease in the release
rate is consistent with the model proposed in Fig. 3, as
the diﬀusion of the solvent into the pores and the
counterdiﬀusion of ibuprofen outside the channels
should be aﬀected by the eﬀective pore size of the ibu-
profen/matrix complex.
For the MCM-41 materials synthesised from C8/C10
mixtures, the delivery is not complete even after a week
of assay, opposite to what has been observed for C16 and
C12 materials, in which the delivery was completed after
3 days. Moreover, after 24 h of assay, the quantities of
ibuprofen delivered to the media by the samples with the
biggest and the smallest pore size are diﬀerent by a factor
of five, Table 2. Therefore, a dosage of this drug as a
function of the pore size of the MCM-41 host can be
aﬀorded, and hence also the amount of drug delivered to
the media at targeted times can be controlled.
Besides, the relation between the amount of ibuprofen
delivered and square root of time is linear ([IBU] ¼
Kt1=2), with regression factors >0.99, pointing to a con-
trol of the delivery process by the internal diﬀusion of
ibuprofen thorough the mesopore channels. The values
of the slopes (K) are included in Table 2, showing the
increase of this slope with the pore diameter.
Fig. 3. Location model of ibuprofen molecules inside the pore channels of diﬀerent pore sized MCM-41.
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Figure 8: Effect of pore diameter on release profile. Diameters are as follows (in nm): MCM-4116 = 3.6, 
MCM-4112 = 3.3, MCM-418(70%)-10(30%) = 2.7, MCM-418(85%)-10(15%) = 2.5, adapted from [22] 
 
An identical conclusion to the relationship between pore size and drug delivery rate was 
reached by comparing the release profiles for the mesoporous silicates MCM-48 and LP-
Ia3d [20]. Here, the analysis was extended with the realization that the pore size alone 
does not determine the drug delivery rate, but the relationship in size between the drug 
molecule and pore diameter. That is, the larger the drug molecule with respect to the pore 
channels, the slower the drug delivery rate. However, with the suppression of delivery 
rate, the maximum drug loading also decreases. The effect of pore size was also 
confirmed by Ukmar et al. in the comparison of MCM-41 with an average pore diameter of 
3.1 nm having a slower release than SBA-15 with an average pore diameter of 9.2 nm 
[21]. 
 
These studies were extended by investigating the effect of surface functionalization of the 
mesoporous silicates on the drug release profiles [19]. The delivery profiles for five 
variations of mesoporous silicates are shown in 9. Here, the “a” after the material name 
denotes that the sample was aged at 363K at a pH of 10 for five days after the material 
synthesis. The “μ” symbol before the material name denotes a microporous material, while 
“m” describes a mesoporous material. Finally, the “c” in cMCM-41a denotes that the 
material was synthesized in the presence of decanoic acid and toluene; the material is 
cationic. The first observation from the figure is that the dependence on pore size shown 
by the previous studies is confirmed in that the microporous materials display a 
significantly faster release than the mesoporous carriers. Secondly, the functionalization of 
for the inclusion of ibuprofen inside the channels seems
to be the hydrogen bond interaction between the ibu-
profen molecule and the silanol groups present in the
pore wall. If the pore diameter is much larger than the
ibuprofen molecule, as it happens for the samples ob-
tained from C16 and C12 surfactants, a close packing of
guest molecules takes place, lining the channels with a
‘‘rim’’ of densely packed molecules which reduces the
eﬀective pore size of the channels, but do not fully oc-
cupy the space available for N2 adsorption [1]. As the
pore size decreases below the threshold value, which
would be close to twice the eﬀective length of the ibu-
profen molecule, close packing of the guest molecules
along the pore wall is avoided by simple geometry con-
siderations. In this case, the pores are blocked for N2
adsorption, but nevertheless empty regions would exist
between the ibuprofen molecules that are present inside
the channels. In this way, the apparent volume occupied
by ibuprofen is higher than that expected from its
molecular size. Fig. 3 illustrates the packing model pre-
valent for the diﬀerent MCM-41 pore size. Nevertheless,
it should be indicated that current research points to the
presence of the ibuprofen as its dimer variety inside
the channel [14], although this fact should not aﬀect to
the drug disposition inside the pores mentioned above.
Fig. 4 displays the kinetics of ibuprofen liberation o
the SBF solution. Data for C16 and C12 materials with
a pore diameter of 3.6 and 3.3 nm respectively have been
included for comparative purposes. It can be observed in
the figure that the delivering rate decreases strongly as
the pore size varies from 3.6 to 2.5 nm. From the initial
portion of the plot the liberation rate can be estimated
to decrease from 24 mg/h for a pore size of 3.6 nm, to 5
mg/h for 2.5 nm. This fivefold decrease in the r lease
rate is consistent with the model proposed in Fig. 3, as
the diﬀusion of the solvent into the pores and the
counterdiﬀusion of ibuprofen outside the channels
should be aﬀected by the eﬀective pore size of the ibu-
profen/matrix complex.
For the MCM-41 materials synthesised from C8/C10
mixtures, the delivery is not complete even after a week
of assay, opposite to what has been observed for C16 and
C12 materials, in which the delivery was completed after
3 days. Moreover, after 24 h of assay, the quantities of
ibuprofen delivered to the media by the samples with the
biggest and the smalle t pore size are diﬀerent by a factor
of five, Table 2. Therefore, a dosage of this drug as a
function of the pore size of the MCM-41 host can be
aﬀorded, and hence also the amount of drug delivered to
the media at targeted times can be controlled.
Besides, the relation between the amount of ibuprofen
delivered and square root of time is linear ([IBU] ¼
Kt1=2), with regression factors >0.99, pointing to a con-
trol of the delivery process by the internal diﬀusion of
ibuprofen thorough the mesopore channels. The values
of the slopes (K) are included in Table 2, showing the
increase of this slope with the pore diameter.
Fig. 3. Location model of ibuprofen molecules inside the pore channels of diﬀerent pore sized MCM-41.
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the MCM-41 with cationic surface significantly suppresses the initial burst and sustains the 
drug delivery for roughly 400 hours, or over two weeks.  
 
 
Figure 9: Drug release profile for various mesoporous silicates: open triangles = cMCM-41a, open 
diamonds = μSBA-1, open circles = MCM-41a, closed circles = μSBA3, closed squares = mSBA-3, 
adapted from [19] 
 
It was found that the drug loading capacity for the microporous materials was lower than 
that for the mesoporous materials. This is due to the pore sizes of >2nm for the 
microporous materials, the size constraints resulted in steric hindrance of the drug 
molecules, preventing high drug loadings. So long that the pores are large enough for 
efficient packing, maximizing the surface area allows the highest drug loading as the 
process is adsorption based [22]. It was also suggested that the drug loading is based on 
adsorption mechanisms based on hydrogen bonding of the carboxyl group of ibuprofen 
and silanol groups of the silica [19]. For the case of the slow release of c-MCM-41a, the 
authors suggest that the synthesis forms 1D cage like pores, which, combined with the 
small pore diameter and high relative loading per surface area, results in slow diffusion 
kinetics and a sustained drug release.  
 
From these studies, it can be seen that the reduction in pore size is advantageous for 
suppressing the burst release observed in drug delivery systems with large pores such as 
was seen in the case of the calcium phosphate based scaffolds. The porosity and its 
associated properties will likely play a large role for the drug release of the nanostructured 
zinc oxide particles under study. 
 
degrees for these samples are 28 wt % for the c-MCM-
41 and 22 wt % for µSBA-3. The isotherms for the
impregnated materials still display the presence of
meso- and micropores, respectively. The marked up-
takes have moved toward lower relative pressures, as
expected. For the microporous SBA-3 type of material,
the total uptake has been remarkably lowered as the
total pore volume was redu ed by almost 75% ( ased
on calculations obt ined from ingl point total pore
volume at p/po ≈ 0.97). For the mesoporous c-MCM-41a,
the reduction was approximately 60% (calculated from
the plateau value obtained at a relative pressure p/po
≈ 0.60). For complete monolayer coverage of ibuprofen,
the reduction in pore diameter should be at least 2 nm
for head-on adsorbed ibuprofen to the pore walls. The
r uction in the calculated average por diameters
(BJH desorption/adsorption plot for the pore size dis-
tribution, Table 1) were about 1-1.5 nm, giving further
support for the conclusion that the ibuprofen molecules
are not present as a close-packed monolayer due to
steric hindrance connected to curvature effects and the
possible formation of tilted ibuprofen due to dimer
formation.48
Drug Release. Typical drug-release profiles for the
different types of investigated materials are plotted in
Figure 5, where all in vitro studies have been performed
under the same conditions. The powders were com-
pressed to disks with a diameter of 13 mm and a
thickness of 3 mm. The respective loading degrees are
given in Table 2. Depending on the material character-
istics, a controlled release is observed for time periods
reaching from 24 h for the majority of ibuprofen
incorporated in the MCM-41a material to above 400 h
for the catanionic c-MCM-41a. The microporous µSBA-3
and µSBA-1 materials and the mesoporous mSBA-3
material all display total release times in the range of
100 h. However, characteristic for mSBA-3 is the
pronounced primary burst effect, corresponding to the
intercept in Figure 5, where almost 20 wt % of the
impregnated ibuprofen will be released within 1 h.
The kinetics of the release of drugs from porous
carrier materials is frequently described using the
Higuchi model.50,51 According to this model, the release
of a drug from an insoluble, porous carrier matrix can
be described as a square root of a time-dependent
process based on Fickian diffusion. The amount of drug
released, Qt, per unit of exposed area at time t can then
be described by the simple relation
where kH is the release rate constant for the Higuchi
model. Thus, for a purely diffusion controlled process,
the amount of drug released exhibits a linear relation-
ship if plotted against the square root of time. The use
of this model should be beneficial for the system under
study as the model is valid for releases of relatively
small molecules that are uniformly distributed through-
out the matrix.51 However, from the Higuchi square root
of time plots presented in Figure 6, it is clearly seen
that all materials display a two-step release. This
deviation from overall linearity is probably related to
the dissolution of the silica matrices during the in vitro
measurements, which will be discussed next.
The silica solubility rates determined for ibuprofen-
containing matrices are shown in Figure 7. The rate of
silica solubility is highest in the early stages, while the
solubility rate decreases with time. This observation can
be ascribed to the sink-type experiment and probably
does not correspond to the dissolution rate in vivo.
However, the rates of silica solubility for the different
materials roughly follow the same order as the release
rates of ibuprofen shown in Figure 5, but it is difficult
to draw any lengthy conclusions on the basis of these
(50) Higuchi, T. J. Pharm. Sci. 1961, 50, 874.
(51) Higuchi, T. J. Pharm. Sci. 1963, 52, 1145.
Figure 5. Ibupr fen release prof les for impregnated mi-
croporous and mesoporous materia s in SBF at 37 °C. (O)
MCM-41a; (3) c-MCM-41a; (9) mSBA-3; (]) µSBA-1; (b)
µSBA-3. The release rate from the MCM-41 sample was
similar to that from the MCM-41a sample and is omitted for
clarity.
Figure 6. Higuchi square root of time plot for the release of
ibuprofen from the studied microporous and mesoporous
materials. (O) MCM-41a; (3) c-MCM-41a; (9) mSBA-3; (])
µSBA-1; (b) µSBA-3.
Figure 7. Amount of silica dissolved measured for ibuprofen-
containing tablets in SBF at 37 °C. (O) MCM-41a; (3) c-MCM-
41a; (9) mSBA-3; (]) µSBA-1; (b) µSBA-3.
Qt ) kH‚"t (2)
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2.3.2 Interactions between drug and DDS surface 
 
 
As has been discussed previously, the type of drug loaded in the system plays a role in 
the drug release properties and a system optimized for a specific drug may not 
necessarily be optimal for a different drug. This is due to the differences in interactions 
between the drug and surface of the delivery system. Namely, the strength of the 
interaction plays a strong role in the drug release properties [23, 24]. 
 
For a system based on hydroxyapatite nanocrystals, it can be observed that the release 
rates for three different drugs (cis-platin, alendronate, and 
di(ethylenediamineplatinum)medronate [DPM]) vary drastically [23]. The chemical 
structure of the drugs and the corresponding release profiles are shown in figures 10 and 
11, respectively. 
 
 
Figure 10: Chemical structure of a) cis-platin b) alendronate, and c) 
di(ethylenediamineplatinum)medronate (DPM), adapted from [23] 
 
The difference in drug release kinetics is caused by the different mechanisms of 
adsorption of the drug onto the surface of the hydroxyapatite nanoparticles. Namely, the 
stronger the interaction between the drug and carrier, the slower the drug release process 
will be. It can be seen in figure 11 that the release rate is fastest for DPM and slowest for 
alendronate. This is because the alendronate molecule fixes to the hydroxyapatite surface 
by strong electrostatic interactions between the negatively charged bisphosphonate 
groups of the alendronate and positively charged Ca2+ ions of the hydroxyapatite. In 
contrast, the cis-platin molecule hydrolizes to form a positively charged species, which 
more weakly fixates to the overall negatively charged hydroxyapatite surface. Thus, while 
For many years, cis-diamminedichloridoplatinum(II) (cispla-
tin; CDDP) has been widely utilized as an anticancer drug de-
spite its nephrotoxicity and other side effects observed for
high-dose treatment; indeed, it is one of the most active antitu-
mor agents in the treatment of osteosarcoma.[9–13] The adsorp-
tion and release of cisplatin by slurries of synthetic HA crystals
in aqueous media has been investigated as a function of ionic
composition and the data indicated that chloride ions reverse
the hydrolysis and that acid dissociation of the aquated species
favors binding to calcium phosphate.[14] Moreover, investiga-
tions carried out using either poorly or well crystallized carbon-
ated HA have shown that cisplatin adsorption increases with
decreasing HA crystallinity and that the less crystalline the ma-
terial, the slower the drug release.[15] This result is particularly
interesting because the poorly crystalline apatite examined ex-
hibits a surface area, morphology, crystallite size and Ca/P mo-
lar ratio close to those observed for bone apatite crystals.
Calcium deficient apatites have also been investigated as
platforms for the specific delivery to bone of geminal bispho-
sphonates (BPs), which are a class of drugs developed for use
in various diseases of bone, tooth, and calcium metabo-
lism.[16,17] BPs are characterized by two phosphonate groups at-
tached to a single carbon atom and have strong affinity for
Ca2+ ions of bone apatite. This property is the basis for their
use as inhibitors of ectopic calcification and of bone resorption.
In general, the physicochemical effects of BPs include binding
to crystals of calcium phosphate and inhibition of their growth,
aggregation, and dissolution. Some BPs, such as alendronate,
have already been approved for clinical use in Paget’s disease,
hypercalcemia of malignancy, and osteoporosis.[18–20] Signifi-
cantly, the basic P–C–P structure of BPs can be widely modi-
fied by changing the substituents at the central carbon atom.
These changes are likely to influence the behavior of BPs in
the biochemical processes. However, studies of the solid/liquid
interfacial properties of HA/BPs conjugates have shown that
differences among the bisphosphonates may also influence
their mechanisms for binding and inhibiting crystal growth and
dissolution. Thus differences among potent bisphosphonates,
such as the apparently more prolonged duration of action of
alendronate and zoledronate compared with the more readily
reversible effects of etidronate and risedronate, can be ex-
plained in part by their ability to absorb onto bone minerals.[21]
Although the mechanisms for binding of cisplatin and alendro-
nate onto different HA surfaces has been separately investi-
gated,[14,15,21] a comparative study of their interaction on o apati-
tic nanocrystals synthesised with variable surface areas and
crystal dimensions within the range of biomimetic parameters,
has not been undertaken even though a detailed solid/surf ce
characterization of these systems would provide important
knowledge for designing new and more effective treatment sys-
tems.Moreover, platinum(II) compounds with aminoph sphonic
acids have also been proposed as ameans for targeting a cytotoxic
moiety to the bone surface.[22,23] These compounds exhibit anti-
metastatic activity and reduce bone tumor volume, and are less
nephrotoxic than cisplatin.[24–26] To our knowledge, experimental
investigations concerning PtII-aminophosphonic acid interactions
withHAnanocrystals have not yet been undertaken.
The aim of the present study is to develop new biomimetic
apatite nanocrystals for potential use in bone impl ntation,
which in addition function as a local targeted delivery system
for anticancer and antimetastatic drugs with controlled release
properties. As already pointed out,[27–29] the adsorption and re-
lease of bioactive molecules are strongly affected not only by
the chemical properties of the drug molecule but also by the
chemical and structural characteristics of the HA substrates.
Thus, in this paper we have investigated the adsorption and re-
lease of cisplatin (Fig. 1a), alendronate (Fig. 1b), and di(ethyle-
nediamineplatinum)medronate (DPM) (Fig. 1c) using two bio-
mim tic synthetic hydrox apatite nanocrystal material with
either plate-shaped (HAps) or needle-shaped (HAns)
morphologies and with different physicochemical surface prop-
erties. Cisplatin and DPM are comparabl in water solubility
(1–2 mgmL–1 and 0.9 mgmL–1 at room temperature, respec-
tively), while alendronate is much more soluble (10 mgmL–1 at
room temperature). The pKa v lu s for the alendronate phos-
phate groups are: pKa1 = 1.35; pKa2 = 2.87; pKa3 = 7.03;
pKa4 = 11.3, whereas no pKa values are reported for the plati-
num complexes because metal ion coordination results in loss
of phosphonate basicity.[30] These bioactive molecules were
chosen in order to compare the behavior of metal based drugs
(CDDP and DPM) with that of a classical organic drug (alen-
dronate), and evaluate the effect of the overall charge of the
drug molecule on influencing the drug affinity for apatite nano-
crystals with variable structural and chemical properties.
2. Results
2.1. Synthesis and Characterization of the HA Nanocrystals
Used as Drug Carriers
HA nanocrystals with nearly stoichiometric bulk Ca/P ratio
(1.67, inductively coupled plasma (ICP) analysis) were synthe-
sized according to two different procedures to produce plate-
or needle-shaped bonelike apatite phases with different physi-
cal properties (Table 1). The surface Ca/P ratios determined by
X-ray photoemission spectroscopy (XPS) analyses were signifi-
cantly lower, indicating calcium deficiency as a result of surface
disorder. In addition, although the bulk Ca/P ratios were simi-
lar, the surface Ca/P ratio was lower for the HAns nanocrystals
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the drug release is characterized by a prolonged release with suppressed initial burst for 
alendronate, its drug release properties for DPM are not as ideal. Comparison of the open 
to closed symbols distinguishes between the release profiles for needle-shaped particles 
with plate-shaped particles, respectively, which doesn’t relate to interactions between the 
drug and DDS. 
 
 
Figure 11: Drug release profile for hydroxyapatite nanoparticles loaded with cis-platin, alendronate, 
and DPM, adapted from [23] 
 
In addition to the variation of the drug for the same drug delivery system, varying 
composition of the DDS also affects the release properties [25]. Here, the synthesis 
procedure was varied to produce various samples from different initial concentrations of 
ibuprofen and OH-, as well as variety in the pH values of the reaction. These conditions 
subsequently controlled the drug loading efficiency, which is, notably, the highest of the 
studies presented so far. With various precursor ratios, samples were produced with 
various ratios of amorphous calcium phosphate to hydroxyapatite to octacalcium 
Binding of the phosphonate groups of alendronate onto the
HA nanoparticles was investigated by analysis of the spectral
features of the O 1s and P 2p XPS peaks (Fig. 5). An intense
band at 530.68 eV was observed for the alendronate-loaded
HAns conjugate (Fig. 5c), which was considered as a convolu-
tion of the alendronate band at 530.37 eV (Fig. 5b), the HAns
band at 531.36 eV (Fig. 5a), and significantly, a band at
531.68 eV originating from alendronate molecules adsorbed
onto the HA surface. The P region of the alendronate-loaded
HA XPS spectra (data not shown) indicated that the binding
energy observed at 133.0 eV was due to the presence of both
the HAns phosphate (133.5 eV) and alendronate phosphonate
(132.3 eV).
XPS analyses were also undertaken on cisplatin-loaded HA
samples. The Pt/N ratios were 0.50 ± 0.05 and 0.60 ± 0.05 for cis-
platin-loaded HAns and HAps, respectively. These data were
close to the stoichiometric values for cisplatin, revealing that
the platinum complex does not undergo Pt–N bond degrada-
tion during adsorption onto the HA nanocrystals. On the other
hand, no chlorine was detected by XPS analyses, clearly indi-
cating that cisplatin undergoes hydrolysis before deposition
onto the HA surface.[14,15] The oxygen region of the spectrum
showed three peaks at 531.0, 533.1 and 534.1 eV, and as cispla-
tin alone has no oxygen signature (spectrum not shown), the
decrease of the first oxygen-peak binding energy from a value
of 531.36 eV in the unmodified HAns, was attributed to strong
interactions between cisplatin and the HA surface. The same
behavior was observed for the P peak at 133.0 eV, which was
0.5 eV lower than that observed for pure HA.
Similar XPS results were obtained for DPM-loaded HA con-
jugates. The Pt/N ratios were 0.40 ± 0.050 and 0.60 ± 0.05 for
DPM-loaded HAns and HAps materials, respectively. These
values were close to those for free DPM indicating that, like
cisplatin, no Pt–N bond degradation occurred during surface
adsorption. However, the P 2p binding energy for the DPM-
loaded HA nanocrystals was 132.8 eV, which was lower than
those observed for pure HA and cisplatin-loaded HA, indicat-
ing that the interaction between HA and DPM was stronger
than that observed for cisplatin.
2.3. Drug Release Profiles
The release kinetics of alendronate, cisplatin, and DPM from
HAps and HAns as a function of contact time in aqueous solu-
tion are plotted in Figure 6. UV-vis spectroscopic analysis indi-
cated that the aqueous species released from cisplatin- or
DPM-loaded HA nanoparticles had an adsorption peak maxi-
mum at 226 nm, which was not present in the blank solution
(HEPES buffer). This band differed from the adsorption bands
characteristic of the two platinum complexes, but nevertheless
was ascri ed to the rel ase of the same platinum complex as
confirmed by ICP-optical emission spectrosc py (OES) d ter-
2184 www.afm-journal.de © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2007, 17, 2180–2188
(a)
(b)
(c)
Binding Energy, eV
537 535 533 531 529 527 525
c
o
u
n
ts
/s
Figure 5. Oxygen 1s spectral region obtained for a) HAns, b) unbound
alendronate and c) alendronate-loaded HAns. Dotted lines were used for
curve fitting and full lines for experimental peaks.
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phosphate. Namely, for the CP-IBU5 sample (mixture of octacalcium phosphate and 
hydroxyapatite), for which the release profile is shown in the upper graph of figure 12, the 
drug loading content was 47% and 196% for CP-IBU13 (pure hydroxyapatite). This means 
that 1.96 grams of ibuprofen was loaded for every gram of calcium phosphate in the 
carrier system. For the CP-IBU5 system, the ibuprofen concentration was 0.1 mol/L and 
OH- concentration was 0.07 mol/L with a reaction pH of 6.6; the CP-IBU13 system was 
produced with an ibuprofen concentration of 0.6 mol/L, OH- concentration of 0.18 mol/L, 
and a reaction pH of 5.7. 
 
 
Figure 12: Drug release profiles for ibuprofen-loaded calcium phosphate drug delivery systems 
produced by one-step synthesis by Tang et al. for CP-IBU5 (top) and CP-IBU13 (bottom), adapted from 
[25] 
 
of the CP-IBU5 and CP-IBU13 DDSs was 60.48 and 98.03 m
2 g-1,
respectively. The ultrahigh DLC of 1.96 g IBU per gram carrier
was achieved for the CP-IBU13 DDS, which is even much higher
than that (1.40 g g-1) of nonbiocompatible mesoporous material
MIL-101, a chromium terephthalate with an ultrahigh SBET of
5510 m2 g-1.13 This extremely high DLC of CP-IBU13 DDS
obviously cannot be accounted for only by SBET.
ACP was reported to form at pH values of 5∼12, and it was
the initial phase of HAp in a neutral or basic environment.
Similarly, it could transform to OCP and DCPD in appropriate
conditions.5,6 The formation of Ca9(PO4)6 cluster of ACP at the
early stage of the precipitation reaction was reported, and the
cluster was estimated to be roughly spherical with a diameter of
9.5 Å.7,8 Wang et al14 studied the formation and transformation
of ACP particles by stopped-flow spectrophotometry, simulta-
neous measurements of particle size and pH of solution, and
high-resolution transmission electron microscopy, indicating the
formation of ion pairs and clusters in the first few seconds, and
crystalline domains developed at multiple sites inside the
primary particles of the amorphous phase. Suppose that the
diameter of ACP clusters is as small as 9.5 Å, ACP clusters have
the lattice similar to HAp and the density of HAp is ρ = 3.16 g
cm-3. The specific surface area of this material is roughly
calculated as high as 2100 m2g-1. We propose that large numbers
of CP clusters with an ultrahigh specific surface area form before
the bulk precipitation occurs in solution, and CP clusters provide
many binding sites for the drug molecules. Ca2+ ions may form
the complex with carboxyl groups of IBU or atorvastatin
calcium. In our experiments the formation of the CP nanocarriers
and the loading of the drug were conducted simultaneously in the
same reaction system. The in situ presence of drug molecules
during the formation of CP nanocarriers may lead to the
interaction between organic groups of the drug molecules and
Ca2+ cations or PO4
3- anions on the surface of the CP clusters.
Thus, the strong interaction between the drug molecules and CP
nanocarriers occurred, and more drug molecules were encapsu-
lated in the interior of the CP nanocarriers in addition to the drug
molecules adsorbed on the surface of the CP nanocarriers, as
shown in Figure 4, which illustrates the proposed strategy for the
one-step simultaneous formation of CP nanocarriers and in situ
drug loading in the same reaction system. It is different from the
conventional DDSs in which the drug molecules merely adsorb
on the surface of the carrier. As a result, a superhigh DLC can be
achieved. The pH value of solution not only influences the
composition, nucleation and crystallization process of the
product, but also changes the ionization state of the IBU and
AC drug molecules; thus, it has a significant effect on the DLC.
The AC molecule is bigger than the IBU molecule, and it has
more functional groups that can interact with the CP nanocar-
riers. A reversed trend in DLC of AC in the CP-AC DDSs
compared with the CP-IBU DDSs in a given pH range is found,
indicating the pH effects in different ways. We demonstrate a
single-step synchronous method for the preparation of CP
nanocarriers and the in situ drug loading conducted in mixed
solvents of water and ethanol.
In comparison with pure IBU without the nanocarriers, which
burns at about 150−280°C in air, the CP-IBU DDS shows a
much higher burning temperature for the IBU ingredient in the
TG measurement, implying that the thermal stability of IBU can
be enhanced to some extent when loaded in the CP nanocarriers
Figure 3. IBU release profiles: (A) CP-IBU5 and (B) CP-IBU13. The insets
show the plots for cumulative IBU release percentage versus natural
logarithm of release time.
Figure 4. Illustration of the single-step synchronous method for the
preparation of CP nanocarriers and the in situ drug loading.
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The first observation in comparing the two delivery profiles is the difference in cumulative 
release, with the CP-IBU5 sample releasing nearly 60% of the ibuprofen by the end of the 
study compared to roughly 18% for CP-IBU13. These results indicate the ability of this 
system to sustain prolonged release of ibuprofen, with 350 hours corresponding to a 
period of 2 weeks. Secondly, the authors denote the loading capacity of the CP-IBU13 
sample as “ultrahigh.” This can be explained by figure 13, where it can be seen that the 
drug is entrapped within the system, and not solely adsorbed on the surface of the carrier. 
FTIR studies suggested that there were both strongly and weakly bounded ibuprofen 
species, which explains the relatively low drug release; only the weakly bounded species 
were released and the strongly bonded molecules remained in the carrier. 
 
 
Figure 13: Drug loading mechanism proposed by Tang et al. for calcium phosphate system based on 
one-step synthesis procedure, adapted from [25] 
 
By varying the synthesis parameters, the authors were able to tune the drug release 
properties, control of which is desirable for the application of a drug delivery system. 
Indeed, the prolonged release combined with the high drug loading ability shown by this 
system is attractive and lends itself well to use as a drug delivery system. 
 of the CP-IBU5 and CP-IBU13 DDSs was 60.48 and 98.03 m2 g-1,
respectively. The ultrahigh DLC of 1.96 g IBU per gram carrier
was achieved for the CP-IBU13 DDS, which is even much higher
than that (1.40 g g-1) of nonbiocompatible mesoporous material
MIL-101, a chromium terephthalate with an ultrahigh SBET of
5510 m2 g-1.13 This extremely high DLC of CP-IBU13 DDS
obviously cannot be accounted for only by SBET.
ACP was reported to form at pH values of 5∼12, and it was
the initial phase of HAp in a neutral or basic environment.
Similarly, it could transform to OCP and DCPD in appropriate
conditions.5,6 The formation of Ca9(PO4)6 cluster of ACP at the
early stage of the precipitation reaction was reported, and the
cluster was estimated to be roughly spherical with a diameter of
9.5 Å.7,8 Wang et al14 studied the formation and transformation
of ACP particles by stopped-flow spectrophotometry, simulta-
neous measurements of particle size and pH of solution, and
high-resolution transmission electron microscopy, indicating the
formation of ion pairs and clusters in the first few seconds, and
crystalline domains developed at multiple sites inside the
primary particles of the amorphous phase. Suppose that the
diameter of ACP clusters is as small as 9.5 Å, ACP clusters have
the lattice similar to HAp and the density of HAp is ρ = 3.16 g
cm-3. The specific surface area of this material is roughly
calculated as high as 2100 m2g-1. We propose that large numbers
of CP clusters with an ultrahigh specific surface area form before
the bulk precipitation occurs in solution, and CP clusters provide
many binding sites for the drug molecules. Ca2+ ions may form
the complex with carboxyl groups of IBU or atorvastatin
calcium. In our experiments the formation of the CP nanocarriers
and the loading of th d ug were conducted simultaneously in th
same reaction system. The in situ presence of drug molecules
during the formation of CP nanocarriers may lead to the
interaction between organic groups of the drug molecules and
Ca2+ cations or PO4
3- anions on the surface of the CP clusters.
Thus, the strong interaction between the drug molecules and CP
nanocarriers occurred, and more drug molecules were encapsu-
lated in the interior of the CP nanocarriers in addition to the drug
molecules adsorbed on the surface of the CP nanocarriers, as
shown in Figure 4, which illustrates the proposed strategy for the
one-step simultaneous formation of CP nanocarriers and in situ
drug loading in the same reaction system. It is different from the
conventional DDSs in which the drug molecules merely adsorb
on the surface of the carrier. As a result, a superhigh DLC can be
achieved. The pH value of solution not only influences the
composition, nucleation and crystallization process of the
product, but also changes the ionization state of the IBU and
AC drug molecules; thus, it has a significant effect on the DLC.
The AC molecule is bigger than the IBU molecule, and it has
more functional groups that can interact with the CP nanocar-
riers. A reversed trend in DLC of AC in the CP-AC DDSs
compared with the CP-IBU DDSs in a given pH range is found,
indicating the pH effects in different ways. We demonstrate a
single-step synchronous method for the preparation of CP
nanocarriers and the in situ drug loading conducted in mixed
solvents of water and ethanol.
In comparison with pure IBU without the nanocarriers, which
burns at about 150−280°C in air, the CP-IBU DDS shows a
much higher burning temperature for the IBU ingredient in the
TG measurement, implying that the thermal stability of IBU can
be enhanced to some extent when loaded in the CP nanocarriers
Figure 3. IBU release profiles: (A) CP-IBU5 and (B) CP-IBU13. The insets
show the plots for cumulative IBU release percentage versus natural
logarithm of release time.
Figure 4. Illustration of the single-step synchronous method for the
preparation of CP nanocarriers and the in situ drug loading.
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2.3.3. Addition of diffusion barriers 
 
 
When the drug must move out of the DDS through diffusion, the addition of barriers to this 
process can control the drug delivery profile. By forming composites with the addition of 
polymeric materials, the drug delivery properties may be even more finely controlled. 
Referring back to the hydroxyapatite scaffolds presented earlier, it was hypothesized that 
the addition of a polymer coating on the scaffold walls would serve to suppress the initial 
burst of the drug release [26, 27]. To test this, the authors impregnated their scaffolds with 
various polymers with various thicknesses. Though different drugs were used—Loca et al. 
studied gentamicin and Dubnika et al. studied lidocaine—both results showed that the 
addition of polymer layers suppressed the initial burst and sustained the drug release over 
longer time periods.  
 
  
Figure 14a: Drug release profiles for polymer coated scaffolds, adapted from Loca et al. [27] 
sustai  the release f the gentamicin. Summarizing results it was observed that gentamicin from 
bioceramic scaffolds was grad ally r leased from 12  to more than 70h depending on the type of 
polymer coating used (see Fig. 4). In spite of different structure of PVA coating such composite could 
sustain the drug release only up to 48h, while that coated with PCL sustain the release of gentamicin to 
more than 70h. Obviously the drug release was influenced by polymer coating solubility properties in 
the aqueous media. 
 
Figure 4. Gentamicin release from polymer coated CaP scaffolds: a) release profile; b) average 
gentamicin release between time points. 
Conclusions 
It was concluded that the presented CaP scaffold manufacturing method and coating technology 
provide a possibility to sustain the gentamicin release up to 70 hours in the case of PCL coated 
bioceramic scaffolds. It was approved that use of different polymer coatings leads to changes in 
gentamicin release profiles. 
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Figure 15b: Drug release profiles for polymer coated scaffolds, adapted from Dubnika et al. [26].  
 
It can be seen from figure 14b that the impregnation of alginate into the scaffold 
significantly suppressed the burst release and even sustained the release to 60 hours. 
While these values remain much faster than was observed for the mesoporous silicates, it 
is a significant improvement on the drug release provided by the hydroxyapatite scaffold 
coated with chitosan preloading. The study by Loca et al. confirms the effectiveness of 
adding a polymer layer to the hydroxyapatite scaffold, with PLA being especially beneficial 
in suppressing the initial burst release. Similarly, Kim et al. coated hydroxyapatite 
scaffolds with a composite of hydroxyapatite and PCL and also found that the coating 
suppressed the initial burst and sustained the drug release [28]. 
 
When considering the use of polymers for biomedical applications such as drug delivery 
systems, an important consideration is biodegradability. For example, while PMMA beads 
have been used for delivery of antibiotics to treat bone infections post surgery, they are 
not biodegradable and required a second surgery to remove the beads after the antibiotic 
delivery was complete [29, 30].  Furthermore, beads based on PMMA displayed 
“unacceptably low” drug release, meaning that a very small fraction of the loaded drug 
was finally delivered. 
 
Biodegradable polymer microspheres were utilized in a study on composite microparticles 
of PLA, PGLA, and PCL [31].  It was found that the complexity of their materials afforded 
more favorable drug release properties; by embedding polymeric ibuprofen-loaded PCL 
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p rsed lidocaine crystals can be obtained. Needle-like
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is used s coating material.
Lidocaine release profiles show that sodium alginate-
coated HAp scaffolds are more promising materials for
drug delivery, and lidocaine release could be sustained
for 60 h.
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nanoparticles within polymeric microparticles of PLGA, it was possible to suppress the 
burst release and sustain drug release for over 96 hours. This can be observed in figure 
16, where the closed diamonds representing this composite material show an optimized 
release profile in comparison to the unencapsulated nanoparticles of ibuprofen-loaded 
PCL. The suppression of burst release can be explained by the double polymer layer 
hindering the drug diffusion. As the ibuprofen is loaded in the PCL nanoparticles, it must 
first diffuse out of these. Then, as the nanoparticles are loaded into the microparticles, the 
drug must subsequently diffuse out of the matrix.  
 
 
Figure 16: Schematic illustration of the synthesis procedure used by Ma et al. in forming hollow 
nanocapsules, adapted from [24] 
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We have successfully prepared for the first time hydroxyapatite (HAp) and calcium silicate (CaSiO3)
nanostructured porous hollow ellipsoidal capsules which are constructed by nanoplate networks using
the inorganic CaCO3 template. CaCO3 ellipsoids are synthesized via the reaction between
Ca(CH3COO)2 and NaHCO3 in water and ethylene glycol mixed solvent at room temperature and they
are used as the Ca2+ source and cores. Then a PO4
3! or SiO3
2! source is added to react with CaCO3 to
form a HAp or CaSiO3 shell on the surface of CaCO3 ellipsoids. Dilute acetic acid is used to remove
remaining CaCO3 cores. The size and shape of the HAp and CaSiO3 hollow capsules are determined by
those of the cores. The thickness of the capsule shell can be controlled by adjusting the concentration of
PO4
3! or SiO3
2! source. A number of PO4
3! sources such as dilute H3PO4, Na3PO4 and Na2HPO4 can
be used to form HAp hollow capsules with similar morphologies. The drug loading and release
behavior of HAp hollow capsules is also investigated. A typical anti-inflammatory drug, ibuprofen, is
used for drug loading. The result indicates that HAp hollow capsules have a high specific surface area
and high storage capacity, and favorable drug release behavior.
1. Introduction
Hydroxyapatite (Ca10(PO4)6(OH)2, HAp) and calcium silicate
(CaSiO3) as inorganic biomaterials have attracted much atten-
tion in recent years owing to their advantages such as chemical
stability, bioactivity, biocompatibility, and potential applica-
tions in bone tissue engineering1,2 and drug delivery.3,4 Nano-
structured hollow spheres of HAp (or CaSiO3) with porous walls
and high specific surface areas are especially desirable for high-
capacity drug loading. In bone reconstruction surgery, HAp (or
CaSiO3) hollow porous nanostructures loaded with treatment
reagents, such as anti-inflammatory drugs, collagen or bone
morphogenetic protein, will be a new concept repair material
which can provide more nanoscale channels to induce embedded
growth of new bones while giving a durative drug or nutrition-
element release to avoid inflammation or other pathological
changes. However, as yet the fabrication of nanostructured HAp
and CaSiO3 hollow capsules with porous shells and high drug
loading efficiency is still a big challenge.
The core–shell technique developed in recent years is an
effective strategy to fabricate hollow nanostructures.5–8 Some
organic cores are adopted as soft templates in the core–shell
technique and they can be easily removed by burning off.9–15
However, most organic core materials are poorly stable due to
their sensitivity to pH, ionic strength and temperature.
Comparatively, using inorganic hard templates to fabricate
inorganic hollow nanostructures is much less reported although
inorganic cores are more stable, rich in shape and more easily
controllable in size and morphology. This is due to one vital
challenge: how to induce the inorganic shell source material to
deposit over the surface of the core while avoiding rapid nucle-
ation and growth of shell material particles in other areas.
Herein, we report an ‘‘opposite ion core–shell’’ strategy for
room-temperature fabrication of HAp and CaSiO3 nano-
structured ellipsoidal holl w capsules using an inorganic
template of calcium carbonate. The strategy is explained in
Fig. 1. The displacement reaction AC + B! ¼ AB + C! takes
place just on the surface of pre-fabricated core AC with
a controlled ellipsoidal morphology and th shell AB f rms. By
removing the cores, ellipsoidal hollow structures are obtained.
The solubility product of the shell compound AB should be much
smaller than that of the core material AC in order to provide
sufficient thermodynamic driving force. In this study, CaCO3
Fig. 1 Illustrati f the ‘‘opposite i n core–shell’’ strategy for the
prep ration of HAp hollow nanostructured capsules using the inorganic
CaCO3 template and their application in drug delivery.
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Figure 17: Release profile for biodegradable polymeric drug delivery systems, adapted from [31] 
PLGA SMP denotes poly(lactide-co-glycolide) simple microparticles, PLGA CMP denotes poly(lactide-
co-glycolide) composite microparticles, and PCL NP denotes poly(ε-caprolactone) nanoparticles 
 
In the case of nanocapsules based on hydroxyapatite, the capsule shell acts as a diffusion 
barrier to the drug loaded within [24]. A schematic for the structure of these 
nanostructures is shown in figure 15 and the corresponding drug release profile is shown 
in figure 17. Clearly, compared the drug release profile of simple ibuprofen, the release of 
discs compacted of the nanocapsules shows a more sustained release with a suppressed 
initial burst. Furthermore, the study reported achieving a loading of 45.95 wt.%, a value 
much higher than those reported in the aforementioned scaffolds. However, the drug 
release was not complete and in fact relatively low, with less than 40% drug released after 
100 hours. The authors suggest that bonding occurs between the –COOH group of the 
ibuprofen molecules with the –OH groups of the hydroxyapatite capsules. Despite this 
relatively low release, the modest release of a large amount of stored drug is more 
favorable than the total release of a very small amount of loaded drug. It is proposed that 
the drug is stored internally within the nanocapsules and that the shell acts as a diffusion 
barrier to the drug release. The release is thus more complex than the simple surface 
desorption proposed for the scaffold-based systems.  
 
dosage form, an ibuprofen solution (Pedea!) was administered
subcutaneously at the same dose (1 mg/kg) in a second group of
rats. The areas under the curves (AUCs) of the concentration–time
profiles were calculated with the linear trapezoidal method. The
relative bioavailability was calculated by the ratio of the respective
AUC corrected by the administered doses. Cmax and Tmax were also
observed as the kinetic parameters of absorption.
3.6.4. Statistical analysis
Results are presented as means ± standard deviation (SD). Mul-
tiple mean comparison was performed by Kruskal–Wallis Test,
followed by the Student–Newman–Keuls test for group ! group
comparisons. A p value <0.05 was considered significant.
4. Results
The main physicochemical parameters (mean diameter, zeta
potential and encapsulation efficiency) of the three types of ibu-
profen dosage forms prepared with the various polymers were
determined. Both unloaded PCL nanoparticles and ibuprofen-
loaded PCL nanoparticles have a diameter around 350 nm
(375 ± 6.0 and 341 ± 9.0 nm, respectively) with almost no charge
("1.3 ± 1.6 and + 2.9 ± 3.9 mV, respectively). The encapsulation
efficiency is high (95 ± 2%).
Ibuprofen-loaded simple and composite microparticles are lar-
ger than unloaded ones. Indeed, the diameter of all ibuprofen-
loaded microparticles is close to 35 lm, whereas unloaded micro-
particles exhibit a smaller size (25 lm). Composite microparticles
have almost the same diameter as simple microparticles for both
ibuprofen-loaded and ibuprofen-unloaded ones. The ibuprofen
encapsulation efficiency in simple microparticles (84 ± 3%) and
composite microparticles (89 ± 2%) is less than PCL nanoparticles
(95 ± 2%) but still relatively high (Table 1).
Fig. 1 displays the release profiles of ibuprofen from ibuprofen
bulk powder, PCL nanoparticles, PLGA simple microparticles and
PLGA composite microparticles. Ibuprofen bulk powder was com-
pletely dissolved at the first sampling point (i.e. 100% at 5 min).
Ibuprofen-loaded PCL nanoparticles display an important drug re-
lease (86 ± 7%) in the first 15 min corresponding to a significant
ibuprofen initial burst effect followed by a plateau up to 24 h (Ta-
ble 2). Different release profiles were obtained with PLGA simple
and composite microparticles. The initial ibuprofen burst release
was more important (21% after 15 min) with PLGA simple micro-
particles than PLGA composite microparticles (9% after 15 min)
with a progressive and controlled release profile up to 24 h for both
types of microparticles (62% and 39% after 24 h for simple and
composite microparticles, respectively). Moreover, a common
trend for all tested microparticles was the non-complete release
of ibuprofen in 24 h as well as a controlled burst effect release with
PLGA composite microparticles and, to a lower extent, with PLGA
simple microparticles.
After subcutaneous administration of the ibuprofen solution
(Pedea!) and the different multiparticular ibuprofen dosage forms,
blood was collected till 96 h. Ibuprofen was only detected in the
blood samples (limit of quantification: 50 ng/mL) during 24 h fol-
lowing the ibuprofen solution or ibuprofen–PCL nanoparticles
subcutaneous administration, whereas it was detected for a much
l nger time (up to 48 h) for PLGA simple microparticles and PLGA
composite microparticles. Fig. 2 shows the mean plasma concen-
trations of ibuprofen after subcutaneous administration (1 mg/
kg) of the solution (Pedea!), the ibuprofen-loaded PCL nanoparti-
cles, the PLGA simple and composite microparticles. During the
first 8 h, the ibuprofen–plasma profiles appeared different with
all dosage forms. The subcutaneous administration of ibuprofen
solution (Pedea!) gave rise to an i mediate peak. The highest
mean plasma concentration (Cmax 8691 ng/mL) for the Pedea! ibu-
profen solution was obtained rapidly (15 min) and then decreased
to 961 ng/mL after 8 h (Table 3). Administration of PCL nanoparti-
cles suspension led to a high initial ibuprofen–plasma level of
about 5070 ng/mL after 45 min. This initial peak was followed by
a gradual decrease in plasma ibuprofen, which reached 1630 ng/
mL after 8 h. Cmax was much lower and much longer to achieve
with PLGA simple microparticles (about 2 h) and PLGA composite
microparticles (4 h) dosage forms (Cmax 2033 and 1249 ng/mL,
respectively). Then, a prolonged plateau, up to 6–8 h, was observed
for composite and simple microparticles indicating a constant re-
lease rate for ibuprofen (Fig. 2B). Plasma concentrations decreased
slowly till 48 h where the quantification limit was reached.
The pharmacokinetic parameters obtained from the plasma ibu-
profen concentrations are summarized in Table 4. Based on the
concentration–time profiles, areas under the ibuprofen concentra-
tion curves (AUCs) were calculated. The AUCs ranked according to
the following order: Pedea! > PCL nanoparticles > simple micro-
particles > composite microparticles. For the first 24 h, the highest
relative bioavailability with regard to the Pedea! solution is ob-
tained with the nanoparticles suspension, whereas PLGA compos-
ite microparticles exhibit the lowest one. Moreover PLGA simple
Table 1
Mean diameter and drug encapsulation efficiency of unloaded, ibuprofen simple
microparticles (SMP) and composite microparticles (CMP) (n = 3 ± SD).
Mean diameter (lm) Encapsulation efficiency (%)
Unloaded Ibuprofen Unloaded Ibuprofen
SMP 24.3 ± 4.7 37.9 ± 2 – 84 ± 3
CMP 27.9 ± 4 33.7 ± 7 – 89 ± 2
Time (hours)
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Fig. 1. Release kinetics of ibuprofen from ibuprofen bulk powder, ibuprofen PCL
nanoparticles (PCL NP), ibuprofen PLGA si ple microparticles (PLGA SMP) and
ibuprofen PLGA composite microparticles (PLGA CMP) for 24 h. Experiments were
performed in phosphate buffer pH 7.4 at 37 "C under sink conditions. Data shown as
mean ± SD (n = 3).
Table 2
Mean percentages of ibuprofen released in vitro after 15 min and 24 h from bulk
powder, PCL nanoparticles (NP), PLGA simple microparticles (SMP) and PLGA
composite microparticles (CMP) (n = 3 ± SD).
Formulations Polymers Ibuprofen released (%)
15 min 24 h
Powde – 100 100
PCL NP PCL 86 ± 6.9 87.5 ± 3.5
PLGA SMP PLGA 21.5 ± 6.1 62.2 ± 7.3
PLGA CMP PCL/PLGA 8.7 ± 4.1 39.5 ± 3.3
340 A. Sheikh Hassan et al. / European Journal of Pharmaceutics and Biopharmaceutics 73 (2009) 337–344
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Figure 18: Drug release profile for a) pure ibuprofen and b) ibuprofen loaded ellipsoidal nanocapsules 
and c) graph of b on axis showing square root of time, adapted from [24] 
 
 
2.3.4. Engineering of the Drug Release Profile 
 
 
From these presented release profiles, it can be seen that several key factors play a role 
in determining its shape. The takeaways from these studies will prove useful in optimizing 
the release profile for the nanocomposite system of ZnO/PU. To summarize: the burst 
effect is more pronounced in systems with larger pore sizes, as easy diffusion is enabled 
by the relatively large cross section of the pores. This was especially apparent in the case 
of mesoporous silicates, where a threshold pore size was found where the ibuprofen 
molecules could not efficiently pack on the pore surfaces due to geometrical constraints. 
Here, the initial burst was especially suppressed due to the difficult diffusion presented by 
the small pores. Finally, by adding additional components to the systems in the form of 
polymeric coatings, an additional diffusion barrier was implemented which suppressed the 
drug release even further. It will be investigated whether these trends apply to the system 
based on zinc oxide embedded in a polyurethane matrix.  
 
 
concentration in simulated body fluid (SBF) was calculated
using:
y ¼ 0.04053 + 1.59696c (1)
where y represents the absorbance value and c represents the
ibuprofen concentration in SBF. The total amount of ibuprofen
released was calculated using:
mt ¼ Ct,V þ n,
Xt#1
1
Ct (2)
where mt represents the total mass of released ibuprofen after
taking out release medium solution (v mL) t times; ct represents
the ibuprofen concentration in SBF at time t; V represents the
total volume of SBF and v represents the volume of release
medium solution taken out for analysis each time.
Fig. 7a and b show the release behavior of the pure ibuprofen
disk and the ibuprofen-loaded HAp hollow capsule disk in SBF.
One can see that the pure ibuprofen disk released much faster
and the release finished within 2.5 h. In contrast, an ibuprofen-
loaded HAp hollow ellipsoidal capsule disk showed a slow and
sustained release of ibuprofen, which can avoid the explosive
release of ibuprofen and prolong the drug effect. A linear
relationship between the cumulative amount of released
ibuprofen and the square root of time was found for the first 12 h,
with a regression factor of 0.99 (Fig. 7c). The ibuprofen release
was governed by a diffusion process in the initial stage. The
ibuprofen was not released completely. This may be explained by
the formation of hydrogen bonds between –COOH groups of
ibuprofen and –OH groups of HAp hollow capsules, which slow
or hold back the release of loaded ibuprofen.
It is important that the property of ibuprofen was not changed
in the loading and releasing processes. Fig. 8a and b show the
UV-vis absorption spectra of ibuprofen hexane solution before
and after ibuprofen loading in HAp hollow capsules and Fig. 8c
and d show the UV-vis absorption spectra of ibuprofen released
in SBF for 2 and 100 h, respectively. In order to show Fig. 8c and
d clearly, we enlarged the absorbance values to eight and three
times the actual values, respectively. One can see that the shape
of absorption curves in Fig. 8 is essentially the same, indicating
that the property of ibuprofen is not changed in the loading and
releasing processes.
4. Conclusions
In summary, using inorganic templates to fabricate inorganic
hollow structures is a challenging work in the inorganic synthesis
field and the ‘‘opposite ion core–shell’’ strategy is a promising
method. The solubility product difference between the shell and
the core is the thermodynamic driving force of the salt–salt ion
replacement reaction. Using the ‘‘opposite ion core–shell’’
strategy we successfully fabricated nanostructured HAp and
CaSiO3 hollow ellipsoidal capsules. The size and shape of the
HAp and CaSiO3 hollow ellipsoidal capsules are determined by
those of the cores, so they are controllable by controlling the size
and morphology of the cores. We can also easily control the
thickness of the capsule shell by adjusting the concentration of
PO4
3# sources. A number of PO4
3# sources, such as dilute H3PO4,
Na3PO4 or Na2HPO4, can be used to form HAp hollow ellip-
soidal capsules with similar morphologies. The HAp hollow
ellipsoidal capsules prepared have a high specific surface area
and a high ibuprofen storage capacity, and favorable drug
release behavior. The synthetic method reported here is simple,
economical and may be scaled up for large scale production of
HAp and CaSiO3 hollow ellipsoidal capsules at low cost, and
therefore holds great promise for applications in drug delivery.
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2.4 Use of Zinc Oxide/Poly(urethane) Material System 
 
 
As the drug delivery system based on ZnO nanoparticles embedded in a polyurethane 
matrix has been proposed, it would be prudent to justify the materials selection as well as 
to review the properties of the respective materials. In the case of zinc oxide, the 
production of monodispersed nanoparticles has shown possible through relatively simple 
synthesis procedures [2]. Additionally, it has been seen that ZnO nanoparticles can be 
loaded with drug for drug delivery applications [32]. Finally, as ZnO is a heavily 
researched material, much is known with respect to its toxicological properties in the 
human body, and, while it has been observed to be a “selective killer” towards cancer 
cells, the nanoparticles are quite safe in the body, especially in the case where they are 
embedded in a polymer matrix [33]. Polyurethane is attractive due to its stability in the 
body and wide range of biomedical applications already reported [34]. Thus, the 
combination of these two materials to form a nanostructured composite drug delivery 
device is a sensible extension of the applications of the individual materials.  
 
 
2.4.1. ZnO 
 
 
While zinc oxide is a popular research topic for semiconducting applications due to its 
wide direct band gap and large exciton binding energy, its use in biomedical applications 
is also prevalent [35]. Specifically, the synthesis of ZnO nanostructures such as 
nanowires, nanorings, and nanoflowers allows development of devices such as field effect 
transistors and even biosensors [36]. ZnO with macroscopic morphologies has use in an 
array of fields ranging from catalysis to cosmetics [43]. In terms of biomedicine, ZnO is an 
attractive material due to its ability to selectively destroy tumor cells [33]. Especially for the 
case of chemotherapeutic drug delivery, the additional anti-cancer activity provided by the 
carrier itself (in the case of using ZnO nanoparticles as a drug delivery system) enhances 
the effect of the drug/carrier system as a whole.  
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Due to the semiconducting nature of zinc oxide, its reduction in size to the nanoscale 
results in the formation of quantum dots (QDs) as the particle diameter becomes smaller 
than the exciton Bohr radius. ZnO QDs are advantageous due to their nontoxicity as 
compared to the more common QDs based on cadmium-selenide of cadmium-telluride 
[38]. Applications in biomedicine envisioned for quantum dots include imaging (due to their 
fluorescence properties) as well as drug delivery (by functionalization of the QD surface). 
 
 
2.4.2. PU 
 
 
The polymer polyurethane, the structural unit for which is shown in figure 18, is formed via 
step-growth polymerization and is typically considered nonbiodegradable for the purposes 
of drug delivery systems due to the fact that the degradation time scale is much longer 
than that of the drug release [39]. Because of this, in cases of where the drug delivery 
system should be eliminated after the drug release (where it has first been implanted in 
the body), a second procedure may be required to remove the polymer. However, 
polyurethane is biocompatible, and has a range of applications in biomedicine ranging 
from vascular implant materials to injectable orthopedic scaffolds [40].  
 
 
Figure 19: Urethane links, adapted from [39] 
 
In terms of its application in drug delivery, systems based on polyurethane have been 
reported in which the drug loading occurs in the polymer itself [34]. This suggests that the 
use of polyurethane as a matrix material in a nanostructure composite drug delivery 
system has as consequence the result that the polyurethane may play an active role in the 
drug delivery process and not simply serve as a containment material for the drug-
containing zinc oxide nanoparticles.  
 
 
Figure 3.
Structures of representative non-degradable pharmaceutically related polymer
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2.4.3. Notable Systems 
 
 
For the delivery system based on zinc oxide nanoparticles, it is interesting to review the 
synthesis of various other zinc oxide nanostructures, as they could offer potential use in 
drug delivery systems. Furthermore, it is of interest to compare the synthesis strategy 
used in the present study with those used by other groups.  
 
It has been seen that mesoporous silicates offer attractive potential for use as drug 
carriers due to their ordered, highly porous nature. The synthesis of analogous 
mesoporous nanospheres of zinc oxide was reported and their potential use as drug 
carriers was highlighted in a study of their use in drug delivery systems [32]. A TEM image 
of the structure can be seen in figure 19, where the ordered assembly of nanocrystals can 
be seen in the right-hand section of the image. It was determined that their system had 
mesopores of an average diameter of 28 nm, of a similar order of magnitude to the pores 
of the mesoporous silicates. These properties have been shown to be beneficial for use in 
drug carriers, and preliminary studies by Barick et al. confirm the potential for the 
material’s use in drug delivery systems. Furthermore, the drug release was found to be pH 
sensitive, which can be utilized for chemotherapeutic uses as the pH values found in 
cancerous tumor cells are typically lower than those in healthy tissue. 
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Figure 20: TEM images of mesoporous zinc oxide nanoparticles as synthesized by Barick et al., 
adapted from [32] 
 
The reported synthesis procedure is relatively straightforward. Diethylene glycol 
containing acetate precursors was heated under reflux until ZnO nanocrystals precipitated 
after reaching temperatures of 160-165°C. After separation from the solution, the 
precipitate was thermally treated to remove excess solvent. This relatively simple 
synthesis procedure afforded itself well to the production of zinc oxide nanocrystals [32].  
 
With biomedical applications in mind, Amna et al. synthesized composite spider web 
scaffolds of ZnO doped polyurethane [41]. The resulting structure, shown in figure 20, can 
be described by the addition of nanofibrous zinc oxide spider webs (shown by the green 
arrow) connecting polyurethane fibers (shown by the red arrow). These mats were found 
to have good biocompatibility through MTT assays, which are experiments to investigate 
cell compatibility. While the study didn’t include any experimentation with drug release, it 
would be interesting to see how this composite material could be used with regard to drug 
delivery systems. Electrospinning was used for the material synthesis by ejecting a 
solution of polyurethane in N,N-dimethylformamide (DMF) with dispersed nanoparticles of 
zinc oxide from a syringe with a high voltage between the syringe tip and a polyethylene 
covered iron drum. This offers a cost-effective and simple method for creating a composite 
material with a complex morphology. 
 
with DOX and DOX-loaded ZnO at different doses to determine
the IC50 values. Different dilutions were prepared in culture
medium using stock solutions of 4 mM DOX and DOX-loaded
ZnO having 4 mM of DOX (to provide an equivalent amount of
drug used) in milli Q water. Media from wells was replaced with
the above solutions prepared in culture medium. Cells were
incubated for another 48 h to determine the cell viability using
the SRB assay. The IC50 values were calculated using
the sigmoidal dose-response equation from Origin 8 software
(OriginLab Corporation, Northampton, MA).
Results and discussion
XRD analysis (Fig. S1, ESI†) reveals the formation of a highly
crystalline single phase hexagonal wurtzite ZnO structure with
average crystallite size of about 20 nm (s ¼ "10%). The lattice
constants of ZnO were found to be a ¼ 3.248(1) !A and
c ¼ 5.205(2) !A, which is very close to the reported value (JCPDS
Card No. 36-1451, a ¼ 3.249 !A and c¼ 5.206 !A). From the SEM
micrographs, fairly well-defined and discrete spherical shaped
assemblies (broad size range: 100–600 nm) comprising of
numerous fine nanocrystals were seen (Fig. S2, ESI†). To probe
this aspect further, TEM was used. Fig. 1 shows (a) a TEM
micrograph of a single ZnO nanoassembly and (b) its magnified
image showing individual nanocrystals assembled in a nano-
assembly. From the TEM micrographs, it can be seen that these
spherical assemblies are highly porous in nature. The pore shapes
are irregular and the pore sizes are not uniform. Each spherical
assembly is made up of 3D spatially connected numerous
nanocrystals of average size #20 nm, which is in good agreement
with the crystallite size obtained from XRD line broadening. The
formation of these spherically-shaped porous assemblies by
oriented attachment of nanocrystals (self-aggregation) during
the course of the synthesis is discussed elsewhere.29 The study
here is focused on the potential application of these porous
assemblies as a novel drug carrier.
To determine the capacity of these porous ZnO nano-
assemblies for the uptake of gases/foreign molecules, such as
drugs, we measured the N2 adsorption–desorption isotherm. The
N2 gas adsorption–desorption isotherms (Fig. S3, ESI†) display
the typical type IV curve accompanied by a type H3 hysteresis
loop, according to IUPAC classification, which is usually
attributed to the predominance of mesopores.30 The presence of
a pronounced hysteresis loop in the isotherm curves is indicative
of a 3D intersection network of the pores,31 which also goes well
with the TEM observation. Furthermore, the pore size calcula-
tions of ZnO assemblies for determination of the mesopores size
distribution were formed on desorption branch of the isotherm
by Barrett–Joiner–Halenda (BJH) method.32 The BJH desorp-
tion dV/dD pore volume vs. pore diameter curve of ZnO nano-
assemblies (ESI, inset of Fig. S3†) shows a broad distribution of
mesopores with an average pore diameter of 28 nm. The surface
area of the pores (SPBJH) and pores’ volume (V
P
BJH) of ZnO were
found to be 27.5 m2 g$1 and 0.22 cm3 g$1, respectively.
About 80% drug-loading efficiency was obtained on reacting
2 ml of an aqueous solution of DOX (2 mg ml$1) with 1 ml of an
aqueous dispersion of mesoporus ZnO nanoassemblies
(10 mg ml$1) for 1 h at room temperature in the dark. We have
also varied the concentration of DOX during loading experi-
ments and observed that the loading efficiency is strongly
dependent on the DOX concentration in solution. Fig. 2 shows
the normalized fluorescence spectra of DOX and DOX-loaded
ZnO nanoassemblies. The fluorescence spectra of DOX-loaded
ZnO show significant differences from that of free DOX. The
interaction of DOX with ZnO is mainly indicated by a predom-
inant quenching of DOX fluorescence in the presence of ZnO,
whereas self-quenching (DOX-DOX interaction due to p–p
stacking) of pure DOX (Fig. S4, ESI†) is not observed. It has
been observed that the fluorescence intensity of DOX decreases
monotonically on increasing the interaction/loading time of
DOX with ZnO until a saturation loading of DOX is achieved.
About 75% of fluorescence quenching is observed from Fig. 2a,
where 10 mg ml$1 of DOX was reacted with 400 mg of ZnO for
30 min and then remains constant on further increasing the
loading time up to 60 min (saturation limits). Furthermore, the
fluorescence intensity of DOX decreases (until saturation is
achieved) on increasing the concentration of ZnO (Fig. 2b:
normalized fluorescence spectra of 10 mg ml$1 of DOX reacted
with different concentrations of ZnO for 15 min), which is
obvious due to the increase in the loading efficiency of DOX into
ZnO. To analyze these spectral changes in more detail, we per-
formed the curve fitting of DOX and DOX-loaded ZnO (10 mg of
DOX reacted with 0, 200 and 1200 mg of ZnO) with Gaussian
profiles and the corresponding results are shown in Fig. 2c and
Table 1, this is intended to accentuate the vibrational fine
structure of the emission band.33 The spectrum of DOX is well
fitted with three Gaussian components situated at ca. 555.4 nm
(band P1), 591.5 (band P2) and 636.9 (band P3). In addition to the
quenching of the spectral intensity, significant changes in band
position and spectral shapes (i.e. change in A1/A2, A3/A2 values,
where A is the area under the respective bands) were also
observed in the fluorescence spectra of DOX-loaded ZnO. These
results suggest that DOX molecules may form some complexes
with ZnO during the loading process due to the interaction of
DOX with ZnO and hence the fluorescence intensity of DOX is
quenched. The fluorescence spectroscopy has been successfully
used to study interactions between DOX and its surroundings in
Fig. 1 (a) A TEM micrograph of single ZnO nanoassembly and (b) its
magnified image showing individual nanocrystals assembled in a nano-
assembly.
6448 | J. Mater. Chem., 2010, 20, 6446–6452 This journal is ª The Royal Society of Chemistry 2010
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Figure 21:FE-SEM micrograph of ZnO doped polyurethane spider web nanostructures produced by 
electrospinning as reported by Amna et al., adapted from [41] 
 
Recent publications (2013) even reported the synthesis of mesoporous nanospheres of 
ZnO for applications in drug delivery [42,43]. These studies have shown that the drug 
release for the carriers is similar to the results reported by Barick et al. and Zhang et al. for 
synthesized ZnO/polymer core/shell quantum dots loaded with doxorubicin [43]. The pH 
response, shown in figure 21 (A), was found to be due to the decomposition of the 
polymer shell at low pH values; the drug release was thus much higher at low pH values. 
The release at neutral pH values was speculated to be due to the weakly adsorbed 
surface molecules.  
 
A pH response has also been reported for zinc oxide nanospheres, however here, the 
drug release of captopril was compared at pH values of 7.4 and 1.2, the drug release 
profiles for which can be seen in figure 21 (B) [43]. For this study, mesoporous 
nanospheres were synthesized by a soluble-starch-insertion method, in which 
Zn(NO3)2*6H2O was added drop wise to a solution of soluble starch dissolved in boiling 
water. By adjusting the pH, a white suspension was formed and the precipitate was 
subsequently separated and heat-treated to induce calcination and obtain ZnO.  
 
electrospun mats was investigated by FTIR spectroscopy. To
investigate the adhesion, proliferation, and growth of the
NIH 3T3 mouse fibroblast on as-spun nanofibrous matrix,
SEM (Leo 435 VP Leo Electron Microscopy Ltd.) was
performed. The samples were coated with a thin layer of
silver–palladium for 180 s at 45 mAwith the Desk II Denton
Vacuum Cold Sputter. After coating, the micrographs were
taken at an accelerating voltage of 10.75 kV.
Results
Morphology and characterization of composite nanofibers
Figure 1 shows the schematic representations for the prep-
aration of Zn-doped PU nanofibers along with the unique
spider webs by electrospinning process. Figure 2 shows the
FE-SEM micrographs of the synthesized PU and ZnO-
doped PU composite spider web nanofibrous mats.
Electrospinning of PU solutions containing 10 wt% of the
polymer afforded well-defined nanofibers with fiber diame-
ter ranging between 400 to 500 nm as demonstrated in
Fig. 2a, b. Pristine PU electrospun fibers obtained had a
smooth surface with uniform diameters along their lengths.
From Fig. 2a, it is clear that the pristine PU mat does not
contain any spider net-like structure, but after the ZnO
doping, it is showing interconnected spider net-like structure
(Fig. 2b). The formation of the spider net-like structure can
be interpreted as due to the ionization of the polymer solu-
tion in the presence of ZnO during electrospinning.
The presence of ZnO nanoparticles in the dispersed com-
posite was further confirmed by XRD, as shown in Fig. 3. In
case of pristine PU, no peak appeared in the spectrum, indi-
cating the amorphous nature of the polymer (Sheikh et al.
2011). Whereas in the Zn-doped PU nanofibers, three strong
bands appeared with maximum intensity at 31.2°, 35.8°, and
56.1° representing Bragg’s reflection from the (100), (101),
and (110) planes, respectively, of ZnO (JCPDS no. 891397)
which implies the presence of crystalline ZnO. This means
ZnO doping has increased the overall crystallinity of the PU
polymer. The successful doping of ZnO with PU was also
confirmed by the EPMA (Fig. 4) spectrum. The EPMA image
clearly shows that carbon is the main element and Zn, O are
also uniformly dispersed on the surface.
The FTIR spectra of pristine and ZnO-doped PU composite
are shown in Fig. 5 recorded at room temperature. The band
position of distinctive functional groups of pristine PU is
identical to those of the composite. This observation suggests
that ZnO doping in PU does not alter its chemical structure.
The FTIR of electrospun PU has characteristic bands at 3,320,
2,960, 1,730, 1,703, 1,530, and 1,220 cm−1, which are
assigned to the ν(N–H), ν(C–H), ν(C0O), ν(C0O), ν(C0C),
and ν(C–C) bonds, respectively (Jiang et al. 2006). It can be
seen that, from the spectra of ZnO-doped PU, the adsorption
of ZnO appeared at the 509 cm−1 band. So, the result of FTIR
spectra suggests the integration of ZnO in the composite
Fig. 2 FE-SEM micrographs of a pristine PU and b ZnO-doped PU
composite nanofibers; the red arrow indicates the main fibers, whereas
the green arrow demonstrates the harbored ultrafine nets
Fig. 3 XRD pattern of pristine and ZnO-doped PU composite
nanofibers
Appl Microbiol Biotechnol (2013) 97:1725–1734 1729
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Figure 22: Drug release profile highlighting the pH dependence for doxorubicin (A) and captopril (B) 
release from ZnO nanoparticles, adapted from [43] (A) and [42] (B) 
 
The captopril release behavior reported by Bakrudeen et al. [42] shows two 
dependencies: the degree of drug loading, either in a 1:5 or 1:2 ratio of drug to carrier, 
which is represented by the black/red and blue/green lines, respectively and the pH 
dependence of the drug release. Contrary to the study of doxorubicin release by Zhang et 
al., the lower pH suppressed the initial burst and sustained the drug release for captopril. 
This is due to the ionizability of the captropril molecule. In a more basic environment, the 
However, after the release of DOX by acid, the color of the
mixture changed back to red, and the corresponding UV/Vis
absorption and PL spectra in Figure 1D are similar to those in
Figure 1B, thus proving that ZnO@polymer decomposes at
pH 5.0, while DOX is stable at this pH. This result confirms
that the DOXmolecules have been released from the surfaces
of the nanoparticles after treatment with acid.
This pH-responsive behavior of ZnO@polymer–DOX
was studied by UV/Vis absorption spectroscopy. The UV/
Vis absorption around 330 nm, which corresponds to the band
gap of ZnO, becomes weaker and weaker when the pH value
of the solution changes from 7.0 to 5.0 (Figure 2A). In
contrast, DOX is stable during the change of the pH value,
and the corresponding UV/Vis absorption band at about
500 nm shows almost no change. The release profile of DOX
from ZnO@polymer–DOX at different pH values shows that
about 15 wt.% of DOXwere released after 10 h at pH 7.0, but
no more DOX was released in the subsequent 30 h (Fig-
ure 2B). We speculate that 15 wt.% of the DOX molecules
were adsorbed weakly on the surface of the nanoparticles,
while the remaining DOX molecules were adhered chemi-
cally on the nanocomposite. In contrast, nearly 90 wt.% of
DOX molecules were released within 10 h at pH 5.0, and
a little more DOX was released slowly and continuously after
that time, which could be ascribed to the adsorption effects
between DOX and the polymer shell. Therefore, our ZnO@-
polymer–DOX is a pH-responsive, degradable system for
DOX delivery and suitable for the specific targeting at solid
tumors.[34]
The cytotoxicities of ZnO@polymer, DOX, and ZnO@-
polymer–DOX were assessed by MTT assays (MTT= 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) after
incubation with U251 cells for 48 h (Figure 3). The ZnO@-
polymer nanoparticles have no visible cytotoxic effect on
U251 cells after 48 h treatment, even at a concentration of
7.5 mgmL!1 (Zn content), and the cytotoxicity of ZnO
nanoparticles is mainly attributed to the zinc ions that were
released from the nanoparticles after dissolution.[35–37] In
contrast, the cytotoxicity of DOX is significant at a small
concentration of 0.5 mgmL!1. Although both free DOX and
ZnO@polymer–DOX exhibit dose-dependent cytotoxicity
toward cancer cells, the cytotoxicity of DOX does not
increase significantly when its concentration is over
1 mgmL!1, while ZnO@polymer–DOX exhibits much stron-
ger cytotoxicity when its DOX concentration is over
2 mgmL!1 (DOX content). As a result, ZnO@polymer–
DOX is able to kill cancer cells effectively at appropriate
concentrations (see right columns in Figure 3), and the side
effects of chemotherapy are suppressed simultaneously. This
phenomenon can be ascribed to the cytotoxicity enhancement
effects of the nanocarriers, which result in the improved
Figure 1. Top: Photographs of aqueous solutions of A) ZnO@polymer,
B) free DOX, C) ZnO@polymer–DOX nanoparticles, and D) DOX
released from ZnO@polymer–DOX at pH 5.0 under white light (left)
and UV light (320 nm; right). Bottom: UV/Vis absorption spectra
(black), excitation (blue), and emission (red) fluorescence spectra of
these samples.
Figure 2. A) UV/Vis absorption spectra of aqueous solutions of
ZnO@polymer–DOX with a decreasing pH value from 7.0 to 5.0.
B) DOX release profile of ZnO@polymer–DOX at different pH values.
Figure 3. Viability of U251 cells after treatment with ZnO@polymer
QDs, ZnO@polymer–DOX composites, and free DOX for 48 h. The
cytotoxicity of ZnO@polymer and ZnO@polymer–DOX were evaluated
with regard to their Zn content (see the lower scale mark). The
cytotoxicity of DOX and ZnO@polymer–DOX were evaluated with
regard to their DOX content (see the upper scale mark).
.Angewandte
Communications
4128 www.angewandte.org ! 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2013, 52, 4127 –4131
attributed to antisymmetric stretching of COO- car-
boxylate radical and symmetric stretching of COO-
group. The appearance of carboxylate radical and
COO- could be because of the reaction resulting in the
opening up of starch chains by alkali. Captopril-loaded
ZnO exhibited the expected absorption bands for the
quaternary carbon atom at 1454 and 1473 cm-1, and
the symmetric CH3-stretching mode with the accom-
panying shoulders at 2881 and 2979 cm-1. The
characteristic cyclocarboxyl group absorption of
captopril (1591 cm-1 in (a)) shifted to 1562 cm-1 in
drug-loaded ZnO structures, while the corresponding
C=O group absorption (1749 cm-1) disappeared,
indicating that entrapped captopril was fully ionized
Table 2 Comparative TGA studies of ZnO-captopril calcined for 2 h at 500 or 600 !C
Samples Decomposition temperature steps
Step I Step II Step III Total decomposition (wt%)
30–260 !C (wt%) 260–500 !C (wt%) 500–800 !C (wt%)
ZnO-capto calcined at 500 !C (a) 1.18 28.11 1.88 31.18
ZnO-capto calcined at 600 !C (b) 0.73 27.81 1.46 30.01
Fig. 5 FT-IR spectra of (a) captopril, (b) uncalcined ZnO,
(c) ZnO calcined at 500 !C, (d) captopril-loaded ZnO that had
been calcined at 500 !C, (e) ZnO calcined at 600 !C, and
(f) captopril-loaded ZnO that had been calcined at 600 !C
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Fig. 6 BET analysis plot of mesoporous ZnO nanospheres
calcined at 500 !C: N2 adsorption–desorption isotherm and pore
size distribution (inset)
Fig. 7 Drug-release profiles, at pH 1.2 and at pH 7.4, of
captopril loaded at specified drug/carrier ratios
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diffusion is more rapid because of the increase in aqueous solubility due to the ionization 
of the –COOH and –SH groups [44]. This goes to show that the drug release can be 
controlled in different manners based on the chemistry of the drug molecule of interest.  
 
 
2.4.4. Summary of Previous Results with ZnO/PU 
 
 
The work by former master’s student Ana Lúcia Mota Pires investigated the drug release 
behavior of a ZnO/PU system [2]. Composite systems were synthesized based on three 
different zinc oxide nanoparticles: a commercially obtained sample denoted ZnOC, a 
sample precipitated from a solution of ZnCl2 and C6H8O7.H2O with NaOH added drop wise 
from a burette, denoted ZnOA, and a sample precipitated from a similar solution with 
NaOH added via a pulverizer, denoted ZnOP. SEM images of the resulting loaded 
particles after being embedded in a polyurethane matrix are shown in figure 22. It can be 
seen that, while the size of the particles themselves is on the order of micrometers, they 
are formed by assemblies of nanoparticles, which confirms the nanostructured nature of 
the system. The corresponding drug release profiles are shown in figure 23. It can be 
seen that the addition of polyurethane had a significant effect on the suppression of the 
drug release as compared to the lone nanoparticles. Additionally, the drug release was 
more sustained for the precipitated samples compared to the commercially obtained 
powder.  
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Figure 23: SEM images of ibuprofen-loaded zinc oxide nanoparticles embedded in a polyurethane 
matrix, adapted from [2] 
 
It can be seen in figure 22 that the particle morphologies varied drastically between the 
commercially obtained powders and those synthesized in the laboratory. Namely, the 
synthesized particles were spherical shaped characterized by agglomerations of 
nanoplates. These resulted in high specific surface areas. The drug loading efficiency 
reported for these particles was roughly 85% for the ZnOC and ZnOA samples and 60% 
for ZnOP samples and it was suggested that the low loading was due to the adsorption of 
citrate ions on the sites where drug (in this case, ibuprofen) would otherwise have been 
adsorbed. Incomplete release—34% for ZnOA and 72% for ZnOC—was due to the strong 
interaction between the drug molecules and the surface of the ZnO carriers, forcing 
incomplete desorption of the drug molecules within the time of the study. 
 
The effect of the polyurethane is easily observed in figure 26 by the drastically lowered 
release rate. This is due to the diffusion barrier provided by the polyurethane matrix. 
Comparing the two precipitated samples ZnOA and ZnOP on the release curves shows 
similar behavior. However, it was already pointed out that slightly different values for drug 
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Figura 46 – Micrografias de vistas de topo dos compósitos a) PU/ZnOC/Ibu, b) PU/ZnOP/Ibu, c) 
PU/ZnOA/Ibu, d) PU/ZnOC/Genta, e) PU/ZnOP/Genta e f) PU/ZnOA/Genta com diferentes ampliações. 
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loading efficiency were reported, with the ZnOA providing more efficient loading, likely due 
to the differences in specific surface area cause by the rate of addition of NaOH into the 
reaction solution during the synthesis procedure. 
 
 
Figure 24: Release profile for ibuprofen-loaded zinc oxide nanoparticles of various compositions as 
well as for the same nanoparticles embedded in a polyurethane matrix, adapted from [2] 
 
While the results from this study show the benefit of utilizing a composite drug delivery 
system in terms of suppressing the burst release and sustaining the drug delivery process 
in general, it remains desirable to optimize the system to promote a more complete drug 
release from these composite materials. For the current study, the particles designated as 
“ZnOP” will be produced and further investigated.  
 
 
2.4.5. Toxicological Considerations 
 
 
For medical materials such as drug delivery systems, the toxicology of novel systems 
must be considered, as the end use in vivo must not be harmful to the body [45, 46]. 
Evaluation of the PU is relatively simple, as its use as a matrix phase means that the 
toxicological properties correspond to those of its bulk form. However, evaluating the ZnO 
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Figura 49 – Perfis de libertação de ibuprofeno (% de fármaco libertado) a partir dos diferentes 
compósitos (PU/ZnOC, PU/ZnOP e PU/ZnOA). 
 
 
Figura 50 - Quantidade absoluta de ibuprofeno libertado a partir de nanopartículas de ZnO e dos 
respetivos compósitos ao longo do tempo. 
O compósito PU/ZnOP/Ibu liberta inicialmente uma maior percentagem de Ibuprofeno do que 
o PU/ZnOA/ibu. Assim, quer as nanopartículas ZnOA/Ibu quer o correspondente PU/ZnOA 
apresentam a menor percentagem de libertação deste fármaco. Sugere-se assim que, 
possivelmente, o ibuprofeno adsorveu mais fortemente na superfície das nanopartículas de ZnOA 
e, consequentemente é menos suscetível de sofrer dessorção como parecem indicar os presentes 
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nanoparticles may not be so straightforward. With the associated change in material 
properties due to size reduction of nanoparticles, the toxicological properties may not (and 
often do not) correlate to those of the material in bulk form.  
 
Several studies have been performed on the toxicological properties of metal oxide 
nanoparticles especially due to their attractiveness as semiconducting materials to be 
used for quantum dots and the various envisioned applications for quantum dots [47, 48]. 
With respect to the use of zinc oxide nanoparticles in a drug delivery system, it was found 
that they are generally nontoxic to the body in general. However, both the studies by 
Chibber et al. and Chang et al. suggest that zinc oxide nanoparticles can be toxic to 
cancer cells, destroying them by the production of reactive oxygen species. These 
potential chemotherapeutic applications are due to the fact that cancer tumor cells are 
more susceptible to death induced by reactive oxygen species than healthy body cells. 
For the purposes of use of zinc oxide nanoparticles in a drug delivery system, it seems to 
be that the nanoparticles are biocompatible. 
 
 
2.5 Modeling of Drug Release Profiles 
 
 
Upon obtaining drug release profiles for DDSs, it is desirable to apply mathematical 
models to the experimental data in order to better understand the drug release 
mechanisms [49]. Namely, the constants found in these models can often be correlated to 
physical parameters of the system and, in this way, the drug release behavior can be 
predicted. A selection of models, which are commonly used in literature, is presented in 
table 1 below. In these equations, the term F is given as the fraction of drug released from 
the system at time t.  
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Table 1: Mathematical Models for Drug Delivery 
Model   Equation  
First Order 𝐹 = 100 ∗ (1 − 𝑒!!!∗!) 
Higuchi 𝐹 =   𝑘! ∗ 𝑡!.! 
Korsmeyer-Peppas 𝐹 = 𝑘!" ∗ 𝑡! 
Baker-Lonsdale 32 1 − 1 − 𝐹100 ! ! − 𝐹100 =   𝑘!" ∗ 𝑡 
Mankoid-Banaker 𝐹 =   𝑘!" ∗ 𝑡! ∗ 𝑒!!∗! 
  
While many additional models exist, these have been selected due to provide a broad 
range of approaches to the models. The first order and Higuchi models are relatively 
simple, yet frequently used models in drug delivery. In the first order model, k1 is simply an 
empirical constant selected in order to fit the data series. However, drug release which 
follows a first order model is known to occur through Fickian diffusion where perfect sink 
conditions are maintained (the drug concentration in the DDS is much higher than in the 
release medium), the drug permeability through the system remains constant, and the 
DDS does not swell or dissolve [50].  
 
The famous Higuchi model, with the empirical constant kH was developed to model the 
release of drug from thin film matrices. Because of this, it would be a surprise to find the 
model a good fit for drug release from nanostructured spheres. The Korsmeyer-Peppas 
model serves as an extension of the Higuchi model by removing the constraint of the 
power constant from 0.5. In this way, there are two constants in the Korsmeyer-Peppas 
model, kKP and n. This allows one to account for the simultaneous diffusion of water into 
the system to induce swelling and drug diffusion out of the system [50]. The proportionality 
constant, kKP, considers the geometry of the DDS, and n relates to the drug diffusion, with 
n = 0.45 designating Fickian diffusion and 0.45 < n < 0.89 describing non-Fickian or 
anomalous diffusion [51]. 
 
In the fourth presented model of Baker and Lonsdale, a single constant exists, kBL, which 
serves to represent physical properties. Namely, 𝑘!" =   3 ∗ 𝐷 ∗ 𝐶! (𝑟!! ∗ 𝐶!), where D is 
the drug diffusion coefficient, CS the saturation solubility, r0 the initial radius for a spherical 
DDS, and C0 the initial drug loading concentration in the DDS.  
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Finally, the Mankoid-Banaker model includes three empirical constants, kMB, n, and k. This 
is a very robust empirical model due to the inclusion of both power and exponential terms.  
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3. Experimental Procedure 
 
 
3.1. Materials Used 
 
 
The materials used in the various phases of the experimental work are listed below in 
table 2.  
 
Table 2: List of Materials 
Material Chemical Formula Source 
Citric Acid C6H8O7 Sigma-Aldrich 
Zinc Chloride ZnCl2 Merck 
Sodium Hydroxide NaOH Sigma-Aldrich 
Ethanol C2H6O Álcool E Géneros 
Alimentares SA 
Ibuprofen C13H18O2 Aldrich 
Poly(urethane) Shown in figure 25, MW 
90,000–140,000 kDa [X] 
Fluka 
Chloroform CHCl3 Carlo Erba Reagents 
1,2-Dichloroethane C2H4Cl2 Fluka 
Phosphate Buffered 
Saline 
0.138 M NaCl, 0.0027 M 
KCl 
Sigma-Aldrich 
 
 
Figure 25: Chemical formula of Tecoflex SG80A polyurethane, adapted from [59] 
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3.2. Sample Preparation  
 
 
3.2.1. Precipitation of ZnO 
 
 
The nanostructured zinc oxide was produced via a chemical precipitation in which 
solutions of ethanolic sodium hydroxide and pure sodium hydroxide were sequentially 
added via a blowing nozzle to a solution of zinc chloride and citric acid, respectively. More 
specifically, a solution of 10 M sodium hydroxide was prepared by dissolving 80 g of 
NaOH pellets in 200 mL of distilled water and allowed to mix for approximately 20 minutes 
via magnetic stirring. Similarly, the ionic solution was prepared by measuring 17 g of citric 
acid and 3.674 g of zinc chloride powders and dissolving in 25 mL distilled water with 
magnetic stirring, ensuring a 3:1 ratio of citrate to zinc ions, respectively. The ethanolic 
solution of sodium hydroxide was prepared by measuring 20 mL of the prepared sodium 
hydroxide solution with 15 mL and then mixing these two solutions, also under magnetic 
stirring. Each solution was allowed to mix for a sufficient duration to ensure complete 
dissolution and mixing of the components, typically between 15 and 20 minutes. 
 
As previously mentioned, the sequential combination of these solutions was completed by 
the addition of the ethanolic sodium hydroxide solution to the zinc chloride/citric acid 
solution and, after the complete addition, the pure sodium hydroxide solution was added in 
order to ensure that a sufficiently high pH was obtained in order to promote the 
precipitation of zinc oxide. These additions were completed with a blowing apparatus, in 
which the zinc chloride/citric acid solution was put in the base of a conical flask under 
stirring and the subsequent solutions were added under blowing at a pressure of roughly 
1.25 bar. This blowing ensured dispersion of the liquid into the flask. The setup can be 
seen in figure 24. The hose coming from the right-hand side of the image connects to the 
buildings supply of compressed air in order to provide the blowing pressure. Prior to the 
precipitation, the connection between the blower and flask was wrapped in aluminum foil 
in order to hinder the escape of vapors that formed during the additions. After the total 
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addition of the pure sodium hydroxide and achievement of a sufficiently high pH, pure, 
crystalline zinc oxide precipitated and the previously transparent solution contained in the 
conical flask became opaque and milky-white. 
 
 
Figure 26: Setup of blowing apparatus for chemical precipitation of nanostructured zinc oxide 
 
The resulting suspension was then centrifuged at 10,000 rpm for 15 minutes in order to 
isolate and collect the zinc oxide powder. Following which, the powder was washed 5 
times by additional centrifuge cycles with fresh batches of deionized water in order to 
remove remaining citrate and sodium ions from the powder. Finally, the powder was dried 
overnight at 50 °C to promote evaporation of remaining water molecules.  
 
A visualization of the complete precipitation procedure is depicted in figure 25. 
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Figure 27: Flowchart outlining precipitation of nanostructured zinc oxide powder 
 
 
3.2.2. Loading of nanostructured zinc oxide with Ibuprofen 
 
 
After collecting the powder from the synthesis suspension, ibuprofen-loaded samples 
were prepared. This was simply done through an adsorption process by soaking the zinc 
oxide powder in solutions of ibuprofen dissolved in ethanol. Ibuprofen was first measured 
and weighed to appropriate values and allowed to dissolve in 50 mL of ethanol in order to 
produce loading solutions with concentrations of 1, 2, 10, and 20 mg/mL. These solutions 
of varied concentrations were prepared to examine the effects of loading concentration on 
drug release; for other experiments, a loading concentration of 10 mg/mL was used. It 
should be noted that the initial procedure specified the dissolution of ibuprofen in distilled 
water. However the solubility limit of ibuprofen in water was found to be <1 mg/mL, which 
is an impractically low value for the purposes of maximizing drug uptake into a drug 
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delivery system. It was found that ethanol provides optimal solvent properties for ibuprofen 
and allows the dissolution of high concentrations of ibuprofen.  
 
It was observed during the loading procedure that the suspension of zinc oxide in the 
loading solution tended to settle to the bottom of the loading container. To ensure that the 
surface of the nanostructured particles were allowed contact with the solution, the loading 
suspensions were subjected to ultrasonic agitation for 60 minutes, twice per day. The 
overall loading process took place over the course of 3 days [2]. In figure 26 can be seen 
the loading suspensions held in the loading containers. These images were produced 
after shaking the containers in order to promote an even distribution of ZnO particles 
throughout the suspension. 
 
 
Figure 28: Loading containers for the loading of ibuprofen into nanostructured zinc oxide 
 
As the ethanol evaporation rate was quite rapid, it was not possible to accurately 
determine the amount of ibuprofen remaining in the suspension (and therefore the amount 
loaded) via UV spectroscopy because the concentration change corresponding to the 
ethanol evaporation provided incorrect values. In other words, the measured 
concentration was not indicative of the initial ibuprofen concentration immediately after the 
drug loading due to the solvent evaporation. Other techniques were thus chosen in order 
to estimate the drug uptake. 
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3.2.3. Formation of ZnO/PU composites 
 
 
The composite systems were formed based on a solvent evaporation method after the 
procedure described by Seil and Webster [52]. For this work, composites were made with 
25 wt% ZnO as well as 50 wt% ZnO embedded in a polyurethane matrix. To summarize: 
commercial polyurethane was dissolved in chloroform with a weight ratio of 2.48 wt% PU 
under magnetic stirring for roughly 30 minutes or until the complete dissolution of the 
polymer could be observed. Then, the prescribed amount of zinc oxide was dispersed in 
1,2-dichloroethane under sonication to form a uniform suspension. The suspension of 
ZnO and solution of dissolved PU were then mixed together with sonication until a 
homogenous mixture formed. This solution was then evenly distributed into 10 mL 
beakers so that the composite could be cast into small discs of roughly 500 μm in 
thickness at the bottom of the beakers. Finally, this was placed in a drying oven overnight 
at 37 °C to allow the solvents to evaporate. This procedure is visually depicted in figure 
27. 
 
 
Figure 29: Flowchart outlining solvent evaporation procedure for production of ZnO/PU composites 
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3.3. Characterization Methods 
 
 
3.3.1. Scanning electron microscopy 
 
 
Scanning electron microscopy (SEM) images were produced in order to elucidate the 
morphologies of both the powder and composite drug delivery systems, which was of 
particular use in observing the degradation processes of the samples during the drug 
release experiments. For this, a Hitachi scanning electron microscope model S-4100 was 
used with a tungsten filament set to an accelerating voltage of 20 keV. The nanostructured 
zinc oxide powder, as it is a semiconducting material, could simply be placed on carbon 
tape attached to the aluminum sample holder with no additional preparation measures 
necessary (i.e. it was not necessary to sputter a conductive layer on top of the ZnO 
powder). The composite materials, on the other hand, underwent carbon sputtering with 
an Emitech K950 carbon evaporator in order to enable SEM imaging through formation of 
a conductive layer over the sample. 
 
The particle sizes and nanoplatelet sizes were determined by averaging the dimensions 
from several samples, as shown in figure 28. Lines were drawn on top of the images and 
measured via the scale bar shown at the bottom of the images. Though not shown 
explicitly with its own figure, a similar technique was used for measuring the nanoplatelet 
width.  
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Figure 30: SEM images of ZnO particles with overlaid lines depicting how dimensions were 
determined 
 
 
3.3.2 X-ray diffraction 
 
 
X-ray diffraction (XRD) was used in order to provide insight into the crystal structure of the 
nanostructured zinc oxide powder. A Rigaku Geigerflex D/Max-SérieC was used with Cu 
Kα radiation corresponding to a wavelength of λ=1.54056 Å. The current and voltage 
applied were 30 mA and 40 kV, respectively. 
 
In order to approximate the crystallite size based on the data obtained through the 
diffraction experiments the Debye-Scherrer equation was used and is given by: 
 𝐶𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑡𝑒  𝑆𝑖𝑧𝑒 =    𝐾𝜆𝛽 cos 𝜃 
 
where K is a shape constant taken to be 0.89 for spherical particles, λ is the radiation 
wavelength, β is the full-width at half-maximum (FWHM), and θ the diffraction angle. 
Though 0.89 is typically assumed to be valid for spherical particles, it is appropriate for 
estimating the size of indeterminate shapes, for which 0.9 is typically used. In the case of 
the particles, though they are spherical by nature, the actual crystallites would more likely 
be defined as the nanoplatelets that agglomerate to form the spherical ZnO particles. 
Secondly, the β constant is often taken as the FWHM including a correction due to 
instrumental peak broadening. However, for the purposes of simply using this equation as 
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an estimation tool for the crystallite size, the effect of the instrument was ignored and β 
was taken simply as the total FWHM, which simply refers to the width of the peak at half 
of its height. In total, the crystallite size was determined for the six largest peaks and the 
average value was taken to be the estimated crystallite size.  
 
 
3.3.3. Fourier Transform Infrared Spectroscopy 
 
 
To investigate the chemical bonding and properties of the samples of nanostructured zinc 
oxide as well as the composite drug delivery systems loaded with ibuprofen, Fourier 
transform infrared spectroscopy (FTIR) was used. As the typical FTIR spectroscopy is 
limited in applicability to solutions, ATR-FTIR (attenuated total reflectance FTIR) was 
utilized on the solid, composite samples. This technique relies on the total reflection of the 
light wave at the sample surface. Upon interacting with the sample, an evanescent wave 
forms within the sample and this is able to probe the chemical environment of the sample.  
The samples were sent to the department of chemistry at the university of Aveiro, where 
they were analyzed with a Bruker Tensor 27, scanning the range from 350-4000 cm-1. 
 
 
3.3.4. Thermogravimetric Analysis 
 
 
Thermogravimetric Analysis (TGA) was used to quantify the weight changes of the various 
samples corresponding to temperature increase. The powder samples of nanostructured 
zinc oxide were measured with a Setaram Labsys DTA/TGA-DSC 1600, using a heating 
rate of 10 °C/minute over the temperature range of 50-400 °C.  
 
With the data provided by TGA, it was possible to determine the amount of adsorbed 
species present in the loaded samples. This was done by subtracting the baseline 
provided by the TGA curve of pure nanostructured zinc-oxide powder from the various 
spectra of loaded samples. The weight loss occurring between 250-300 °C could then be 
attributed to the decomposition of the organic ibuprofen molecules [53]. However, as will 
be shown in the following chapter, this method provides complications in that the weight 
Chapter 3 – Experimental Procedure 
 
56 
 
loss step for the loaded samples cannot be attributed solely to ibuprofen, degradation of 
remaining citric acid must also be taken into consideration. 
 
In order to minimize the amount of adsorbed water molecules, the samples were dried in 
an oven at 65 °C overnight prior to delivery to the technician responsible for TGA 
measurements. 
 
 
3.3.5. Gas Sorption Analysis	  
 
 
Gas sorption experiments were used in probing the porosity of the nanostructured zinc 
oxide powders. A Micromeritics Gemini 2370V5 gas analyzer was used with measurement 
temperature of -195.85 °C and preparation evacuation rate of 1000 mmHg/min for 10 
minutes. Adsorption isotherms were produced which compare the amount of gas 
adsorbed by the sample surfaces with respect to the relative pressure of the gas in the 
sample chamber. Here, N2 was used as the analyzing gas.  
 
 
3.3.6. Ultraviolet-Visible Light Spectroscopy 
 
 
For the purposes of using UV-VIS spectroscopy to characterize drug delivery devices, the 
interest is not in using the spectrum for compositional determination, but to quantitatively 
determine concentrations of drug present in the elution solutions. For this, Beer’s Law is 
used, which states that the amount of light absorbed is proportional to the number of 
molecules in the system, which can be written as the following equation: 
 𝑇 = 𝑒!!"# 
 
where T is the transmittance, k is a constant, b is the path length, and c is the 
concentration of the absorbing molecules. To use this equation to determine the drug 
concentration, the absorption is measured at a wavelength specific to the drug of interest. 
Finally, to create a drug release profile, a plot of the concentration values vs. time is 
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created, where time axis is enabled by taking samples at predetermined intervals after 
beginning a drug release experiment.  
 
For measuring the concentration of ibuprofen in PBS, the 219 nm was chosen as the 
wavelength. This wavelength was selected due to the high signal of ibuprofen at this point, 
which was found by analyzing a spectrum from 190-350 nm. Sets of calibration curves 
were made to associate the respective absorption values at 219 nm with known 
concentrations of prepared samples. Thus, by using Beer’s law, it was possible to 
determine the concentration of unknown samples by referencing the absorption value to 
the according calibration curve.  
 
A Shimando UV-3100 was used with the software UVProbe 2.10 for these measurements. 
Although only the absorption at 219 nm was of interest, spectra from 190-350 nm were 
obtained for each sample. In this way, it was possible to compare the shape of the spectra 
to that of the prepared calibration samples for ibuprofen in PBS. Where the shape 
diverged significantly from that of the known samples, it was assumed to have had 
problems with contamination. 
 
 
3.3. Drug Release Experiments 
 
 
For the drug release experiments a standard procedure in the field of drug release studies 
was used in that the drug delivery systems were placed in a phosphate buffered saline 
solution (PBS) and aliquots of the release medium were taken at regular intervals for UV 
analysis to determine the drug concentration present at these times. Specifically, for the 
experiments on loaded powder (as opposed to the composite DDSs), 100 mg of loaded 
ZnO was measured and placed in a dialysis membrane with roughly 5 mL of PBS. The 
membrane was then submerged into 200 mL of PBS in a conical flask, as shown in figure 
29. This setup was then placed on a shaking table and shaken at 125 rpm in an 
environmental chamber maintaining a constant body temperature of 37 °C. 
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Figure 31: Setup for drug release experiments. A: Powder samples placed in dialysis membrane and 
then submerged in PBS; B: composite samples simply submerged in PBS 
 
Similarly, for the drug release experiments with the composite DDSs, conical flasks 
containing 200 mL of PBS were used. However, for the composites, the DDSs were 
simply placed in the PBS solution without the use of dialysis membranes.  
 
In both the cases for powder and composite samples, 4 mL samples were taken at 
predetermined intervals and analyzed via UV-VIS spectroscopy in order to determine the 
concentration of ibuprofen. Drug release curves were then built from these values.  
 
 
3.4. Data Modeling 
 
 
After obtaining the drug release curves for the experiments, it was attempted to fit various 
models found in literature to the experimental data. An assortment of reported models 
were selected and have been given with the corresponding equations in table 1, in chapter 
2. The models were selected from [49] and the reasoning behind their selection was also 
presented in chapter 2.  
 
The curve fitting was performed with Microsoft Excel, where the “Goal Seek” function was 
applied to the respective parameter(s) for each model in order to maximize the R2 value 
A) B) 
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for the modeled data set. The optimized R2 values are reported in the appendix in table 8. 
In other words, a data set was created to provide modeled ibuprofen concentrations at the 
same time points present in the various drug release experiments. Minimization of the 
difference between the modeled and experimental data set then allowed the parameters 
of the various models to be determined.  
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4. Results and Discussion 
 
 
To best report the experimental results in a logical fashion, this chapter will be divided into 
four sections. Firstly, the results from various characterization methods will be presented 
for the nanostructured ZnO particles, followed by the characterization results of the 
composite ZnO/PU drug delivery systems. Then, the drug release experimental results will 
be given, which includes those of both the systems based on pure nanostructured ZnO 
and the composites as well as the application of various models proposed in literature. 
Finally, this chapter will conclude with a discussion of the degradation behaviors observed 
during the drug release experiments for the particle and composite systems.  
 
 
4.1 Characterization of the Nanostructured ZnO 
 
 
4.1.1. X-Ray Diffraction 
 
 
 
Figure 32: XRD Spectrum for pure nanostructured ZnO with peaks labeled according to diffraction 
planes 
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The XRD spectrum for the precipitated ZnO powder can be seen in figure 30. The peaks 
correspond well to the reported positions of literature for pure crystalline zinc oxide 
according to the JCPDS file number 00-036-1451. Using the Scherrer equation (eq. given 
in previous chapter) in order to determine average crystallite size suggests a crystallite 
size of 27 nm, which was calculated by averaging the values obtained for the six largest 
peaks.  
 
The fact that pure, crystalline ZnO was produced is significant due to the fact that the 
synthesis of oxides frequently requires a calcination step, in which a heat treatment is 
applied to the material in order to promote oxidation [18, 42, 55]. In the present case, 
however, no additional high temperature steps were required to form pure zinc oxide. This 
would be advantageous in practical use in terms of ease of processing the drug delivery 
system.  
 
 
4.1.2. Scanning Electron Microscopy 
 
 
SEM images were produced in order to investigate the microstructure of the 
nanostructured ZnO particles. In figure 31 is shown SEM images for pure ZnO produced 
one day after the chemical precipitation. The left image shows the overall particle 
morphology and a magnified view of the particle surface is shown in the right section. The 
particles can be described by an agglomeration or assemblage of plate-shaped nanoscale 
pieces, which come together to form spherical forms of approximately 2.7 micrometers in 
diameter. It should be noted that the platelets present a radial orientation, meaning that 
one of the long edges points towards the center of the spherical particles, which provides 
channels and easy access to surfaces within the body of the particles. Because of these 
nanoscale features, it is expected that the nanostructured particles have a high specific 
surface area, which will be discussed in more detail in the section regarding gas sorption 
measurements.  
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Figure 33: SEM image of pure nanostructured ZnO particles. Left: magnification of x10000 to show 
overall particle size; right: magnification of x50000 to show particle surface morphology 
 
Following the procedure outlined in the experimental section, the particle dimensions were 
calculated and are shown in table 3. 
 
Table 3: Dimensional details of ZnO nanostructured particles 
Dimension Calculated Value Standard Deviation 
Particle Diameter 2.7 μm .9 μm 
Nanoplatelet Length 680 nm 200 nm 
Nanoplatelet Thickness 38 nm 12 nm 
 
These platelet dimensions estimated from the micrographs are slightly larger than the 27 
nm determined by the Scherrer equation based on the diffraction data discussed in the 
previous section. Though it has been proposed that the accuracy provided by the Scherrer 
equation leaves much to be desired [56], the estimation obtained based on the XRD data 
in fact provided a prediction for the average crystallite size that corresponds quite well to 
the thickness of the nanoplatelets. This suggests that indeed the particles are an 
assembly of individual nanoplatelets and that the designation as “nanostructured” can be 
justified. It can be noted that the nanoplatelet thickness (38nm) is very close to the 
average crystallite size (27nm) determined by the Scherrer equation.  
 
Micrographs were produced for the loaded particles as well (containing ibuprofen). As can 
be seen in figure 32, the drug loading process does not alter the microstructure of the drug 
carrier. The particle size remains constant (no swelling and no disaggregation) and the 
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structure of agglomerated nanoplatelets’ assemblage is maintained. In fact, the loaded 
particles are indistinguishable from their virgin counterparts.  
 
Furthermore, in the left portion of figure 32 can be seen a less magnified view of the 
particles, where the uniformity of particle size can be observed. Comparing the images of 
figures 31 and 32 reveals the consistency in particle size, even between precipitation 
batches. Because of this, subsequent experiments with drug release could be made 
without concern that significant variation in particle morphology between synthesis 
batches would significantly impact the results.  
 
   
Figure 34: SEM images of nanostructured ZnO particles loaded with IBU at 800 ug/mL. Left: 
magnification of x2000; right: magnification of x10000 
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Figure 35: SEM of nanostructured ZnO particles precipitated from supernatant solution post-
collection 
 
To explore the process efficiency regarding the yield of ZnO precipitated during the 
procedure, after the initial powder was collected from the suspension resulting from the 
precipitation procedure the leftover supernatant was heated in order to promote the 
crystallization of additional zinc oxide. Indeed, this was possible; crystalline ZnO powder 
particles were precipitated, as confirmed by XRD and the microstructure of this ZnO is 
shown in figure 33. However, the amount of powder collected was too little for it to be 
viable for drug delivery experiments. As can be seen, the overall particle sizes of the ZnO 
precipitated from the supernatant are quite similar to the particles produced during the 
initial precipitation. However, the definition of the nanoplatelets is reduced; it can be seen 
that the spherical particles are, as in the initial precipitate, formed by an agglomeration of 
nanosized particles, but it cannot be said that these are nanoplatelets. The shape of these 
sub-particles is more ambiguous.  
 
An explanation for this occurrence can be as follows. During the initial precipitation, the 
presence of citric acid ions, which is known to have a strong tendency to form chelated 
complexes with cations, gives rise to the formation of Zn-based complexes during the 
room-temperature precipitation. Thus, after the removal of the ZnO powder, an amount of 
Zn still is present in the supernatant solution. With a temperature increase, the complexes 
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of Zn and citric acid become unstable, releasing Zn2+ ions back into the solution, which 
leads to a supersaturation of Zn2+ and promotes the further precipitation of ZnO. 
 
4.1.3. Fourier Transform Infrared Spectroscopy 
 
To analyze the chemical bonding information in the samples, FTIR was used. Figures 34 
and 35 show the spectra for the samples of pure nanostructured ZnO, ZnO loaded with 
ibuprofen at 1 mg/mL, and ZnO loaded with ibuprofen at 10 mg/mL, respectively. The 
characteristic absorption peak for the Zn—O bond occurs from 450-500 cm-1, which can 
be seen in all cases as the sudden drop in that range, as the scanning range of the 
equipment did not account for the full peak. Additionally, the three samples show a broad 
absorption from 3000-3750 cm-1 that is due to O—H bonds from hydroxyl groups. The 
peaks labeled “b” and “c” can be assigned to the bending of water molecules and 
absorption of the C=O bond in carboxyl groups, respectively. The latter can be attributed 
to the presence of residual adsorbed citrate ions. 
 
 
Figure 36: FTIR spectrum of pure nanostructured ZnO particles 
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Table 4: FTIR peak assignments for ZnO 
Designation wavenumber (cm-1)-1) Assignment [55,57,58] 
a 3600 
Characteristic absorption of hydroxyl (O-H) 
groups 
b 1560 Bending of water molecules1 
c 1396 Absorption of C=O1 
d < 500 Absorption of Zn-O bond 
 
   
Figure 37: FTIR spectra of IBU loaded ZnO DDSs. Left: loaded in 1 mg/mL; right: loaded in 10 mg/mL 
 
After the IBU loading, the resulting FTIR spectra show no significant deviation in the 
positions of absorption peaks. Though the shape of the peak attributed to Zn-O bonds 
located at the right extreme of the graphs remains consistent, the intensities of the three 
other main peaks diminishes slightly due to the drug loading. This can be seen especially 
well in peak “a” which was assigned to O-H hydroxyl groups, where the peak intensity 
decreases with a corresponding increase in amount of IBU. It could be that the attachment 
of residual water molecules post-precipitation is reduced with the replacement of IBU 
molecules on the same sites. The same decrease in peak intensity can be seen for that 
labeled “b.” As this signal intensity is proportional to the number of C=O bonds in the 
carboxyl groups, and citric acid has three C=O bonds while ibuprofen has only one, the 
decrease in the absorption at ~1400 cm-1 suggests the replacement of adsorbed citric acid 
with ibuprofen.  
                                                
 
1 These peaks are ambiguously reported in literature, however it is agreed that they are 
due to residual impurities due to atmospheric molecules such as H2O or CO2 
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Additionally, two small peaks appear in the spectra for IBU-loaded samples. These can be 
seen at ~2950 and ~2850 cm-1, which can be assigned to the asymmetrical stretching of 
CH3 groups and symmetrical stretching of CH2 groups, respectively [53].  
 
 
4.1.4. Gas Sorption Experiments 
 
 
   
Figure 38: Gas sorption isotherms for powder ZnO DDSs. Left: Unloaded; right: loaded in 1 mg/mL 
(blue) and 10 mg/mL (red) 
 
Gas sorption experiments, for which the isotherms are presented in figure 36, were 
performed in order to provide information regarding the porous nature of the 
nanostructured ZnO particles. From the isotherms it was possible to calculate important 
properties such as specific surface area, pore volume, and pore cross sections, which are 
presented in table 5.  
 
Table 5: Porosity details of unloaded and loaded ZnO particles 
  Sample BET SSA (m2/g) Pore Volume (cm3/g) Pore Cross Section 
(Å) 
Pure ZnO 19 0.06 97 
Loaded – 1 mg/mL 30 0.16 162 
Loaded – 10 mg/mL 25 0.13 150 
  
Comparisons between the loaded samples indicated that pore volume, cross section, and 
BET specific surface area are smaller for the sample that was subjected to higher loading 
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concentrations. It follows that, for the samples loaded in solutions of higher 
concentrations, the overall amount of drug present in the carrier post-loading should be 
higher. This can already be seen to be true in the gas sorption results, as the larger 
amount of loaded drug fills the pores more completely, closing the system and thereby 
reducing the apparent pore volume and cross section observed by the measurements. 
However, this trend is unfortunately contradicted by the data for unloaded ZnO, where it 
would be expected to have a larger pore volume and BET specific surface area than the 
loaded samples. This could indicate that the internal structure is not as consistent 
between synthesis batches as initially suggested by the SEM results; the data for the pure 
ZnO sample was taken for one of the first samples produced and was performed several 
months before the loaded samples.  
 
Though, as shown by the FTIR spectra, the drug loading comes with an associated 
decrease in the amount of citric acid attached to the sample. A possible explanation for 
the increase of specific surface area associated with the loaded samples could be that the 
release of citric acid frees additional surface area in the sample more than that which is 
occupied by adsorbed ibuprofen. 
 
 
4.1.5. Thermogravimetric Analyses 
 
 
To investigate the thermal behavior of the samples, thermogravimetric analyses were 
performed, the results for which are presented in figures 37 and 39-43. Additionally, a 
differential thermal analysis spectrum is presented in the same figure for pure ibuprofen, 
shown in figure 38.  
 
In the case of pure ZnO, the TGA for which can be seen in figure 37, a few important 
observations can be made. Namely, there is a constant general decrease in weight 
throughout the temperature change. At low temperature, up to roughly 250 °C, the weight 
loss can be attributed to the evaporation of physically and chemically adsorbed water 
molecules as well as remnant organic species from the precipitation procedure, mainly 
ethanol. A sharp step occurring between 260 and 270 °C can be accounted for by the 
decomposition of citric acid leftover from the synthesis. At higher temperatures, the weight 
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loss is also due to the continued combustion of citric acid, which continues through the 
range of the experiment. The broad steps can be explained by the fact that a constant 
heating rate is maintained throughout the experiment and that it takes time for the reaction 
products to escape the porous structure of the nanoparticles. 
 
 
Figure 39: TGA curve for pure ZnO particles 
 
 
 
Figure 40: TGA (dotted line) and DTA (solid line) for pure IBU 
 
The unfortunate circumstance is that the step due to decomposition of citric acid occurs in 
a similar position to that for the decomposition of ibuprofen, as seen in figure 38. This 
forces difficulties for the quantitative determination of the amount of ibuprofen loaded in 
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the samples. Additionally, it was seen in the FTIR results that the drug loading procedure 
is associated by replacement of adsorbed citric acid species, which prohibits the 
assumption that the step in the pure ZnO due to citric acid decomposition can be taken as 
a baseline step for all of the subsequent samples due to the different initial concentrations 
of adsorbed citric acid in the various samples. It would be beneficial to investigate 
methods of cleaning the citric acid from the precipitated ZnO particles in order to enable 
quantitative determination of ibuprofen loading through TGA.  
 
 
Figure 41: TGA curve for ZnO particles loaded with IBU at 1 mg/mL 
 
   
Figure 42: TGA curve for ZnO particles loaded with IBU at 2 mg/mL 
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Figure 43: TGA curve for ZnO particles loaded with IBU at 10 mg/mL 
 
Figures 39-41 show the TGA curves for the ZnO particles loaded with ibuprofen with 
various concentrations: 1, 2, and 10 mg/mL in ethanol. The three graphs share the 
general trend of broad weight losses occurring before and after the main step occurring at 
roughly 300 °C. These follow the same explanation as was given for the sample of pure 
ZnO with the slight exception that the decrease at high temperature also includes 
continued combustion of the organic ibuprofen molecules. The most significant point of 
comparison between these three figures is the steep step found at 300 °C. Namely, the 
height of this step differs between the three samples. Considering the hypothesis that the 
higher concentration of ibuprofen in the drug loading solution enables a higher loading, the 
larger step seen in figure 41 can be explained by the decomposition of a higher amount of 
ibuprofen.  
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Figure 44: TGA curve of ZnO particles loaded with IBU at 10 mg/mL followed by 1 wash cycle 
 
   
Figure 45: TGA curve of ZnO particles loaded with IBU at 10 mg/mL followed by 3 wash cycles 
 
Comparison of figures 41-43 shows the effects of washing on the thermal properties of the 
ZnO particles. Again, the general behavior of the spectra follows the previous explanation 
and the point of interest is once more the step around 300 °C. Firstly, the step height is 
lower in the washed samples than in the unwashed sample. As the loading concentration 
for these samples, it can be concluded that the washing procedure serves to remove 
organic compounds. Though, whether it is citric acid, ibuprofen, or a combination of both 
that is removed remains unclear. Secondly, the onset of the weigh-loss step is shifted to 
higher temperatures in the washed samples. As the chemical history of the washed 
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samples was identical to the unwashed samples, an explanation for this could be that the 
washing procedure alters the microstructure and pathways for the release of 
decomposition products. The analysis of the particle morphologies of washed samples will 
be provided later. 
 
Table 6: TGA weight loss due to decomposition of IBU and correlated estimated loading of IBU 
Sample TGA Weight Loss (%) 
Estimated Relative Loading  
(mg IBU/mg ZnO) 
1 mg/mL 2.18% 0.022 
2 mg/mL 2.46% 0.025 
10 mg/mL 3.66% 0.038 
10 mg/mL, 1 wash 2.82% 0.029 
10 mg/mL, 3 wash 1.20% 0.012 
 
Despite the complications arising from the presence of unknown quantities of citric acid in 
the samples, the estimated loading IBU was calculated according to the procedure 
outlined in the previous chapter in order to provide a comparison for the tool for the results 
of the drug release experiments. These data are presented in table 6. The general trend 
shows that the increased IBU concentration in the ethanol loading solution enables a 
higher uptake of drug into the delivery system, which is observed by the larger weight loss 
step at 300 °C. By comparing the samples of 10 mg/mL and 1 mg/mL, for example, it is 
shown that a ten-fold increase in the loading concentration results in a 70% increase in 
drug uptake. Similarly, the washing procedures clearly show that some of the drug is 
removed from the loaded samples, and an expected reduction in drug release will be 
seen. However, because of the step observed in the virgin sample attributed to 
decomposition of citric acid is located in a similar range as the expected step due to the 
decomposition of ibuprofen, the accuracy of the loading values presented in the right-hand 
column of table 5 cannot be claimed with high confidence.  
 
It would be of high interest to develop a method in order to more accurately perform these 
calculations so that a relationship could be made between the loading concentration and 
the loading amount, as well as to determine the maximum amount of loading that is 
possible for this materials. Firstly, the potential for this material in biomedicine can be 
evaluated based on the drug loading potential. In other words, the more drug that can be 
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stored in the system affords the most useful system. However, that is not to say that the 
system would need to be loaded at it’s maximum potential in all applications. By being 
able to fine-tune the amount of drug loaded, it would be possible to vary the drug dosage 
stored in the system for customization of the therapeutic application of the DDS. 
 
 
4.2. Characterization of ZnO/PU Composites 
 
 
4.2.1. Scanning Electron Microscopy 
 
 
SEM micrographs were produced for the composite ZnO/PU DDSs and are shown in 
figure 44, in which images for both the 25 wt% and 50 wt% samples are shown at 
magnifications of x500 and x10000. Here, as in the rest of this work, the wt% designation 
refers to the relative amount of loaded ZnO present in the composite system. In the left 
side of the figure can clearly be seen the effect of increased quantities of ZnO. Namely, 
the density of nanostructured particles is much higher for the 50 wt% sample. On the right 
side can be seen a magnified view of the ZnO particles. There is an apparent lack of 
sharpness for these particles, which is due to the fact that these images were taken from 
the top surface of the composite. During the solvent evaporation procedure the particles 
towards the upper surface became completely covered by polyurethane and their 
nanostructured morphologies can therefore not be distinguished on the SEM images of 
the composite materials.  
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Figure 46: SEM images of ZnO/PU composite DDSs at magnifications of x500 and x10000. Top row: 25 
wt% ZnO; bottom row: 50 wt% ZnO. 
 
For the ZnO particles, it can be observed that they are evenly distributed across the 
sample. The polyurethane itself is rather featureless, but in the more highly magnified view 
in the figure one can observe that it is not perfectly smooth. This will be discussed in more 
detail in the section regarding composite degradation during drug release. Suffice it say, 
the composite serves to embed the ZnO nanostructured particles in a homogenous 
fashion.  
 
 
4.2.2. Fourier Transform Infrared Spectroscopy 
 
 
FTIR analyses were performed on the composite samples in order to investigate the 
chemical interaction between the various components of the composite systems. These 
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are presented in figures 45-47. The spectrum for pure, commercial PU is shown in figure 
45 with the corresponding peak assignments provided in table 7. 
 
 
Figure 47: FTIR spectrum of pure, commercial PU 
 
Table 7: Absorption peak assignments for FTIR spectrum of PU 
Designation wavenumber (cm-1) Assignment [59] 
a 3449 Free NH stretching 
b 3310 H-bounded NH stretching 
c 2931 
Asymmetric β CH2 Stretching (polyether) + 
asymmetric CH2 stretching (cyclohexane) 
d 2851 
Asymmetric α CH2 stretching (polyether) + 
symmetric β CH2 stretching (polyether) + 
symmetric CH2 stretching (cyclohexane) 
e 2800 Symmetric α CH2 stretching (polyether) 
f 1714 Free C=O stretching (amide I region) 
g 1699 H-bounded C-O stretching (amide I region) 
h 1525 C-N stretching + N-H bending (amide II band) 
i 1448 CH2 bending 
j 1369 CH2 wagging 
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k 1319 C-C stretching (cyclohexane) 
l 1248 CH2 wagging 
m 1228 C-N stretching (Amide III band) 
n 1103 Asymmetric C-O-C stretching (polyether) 
p 1045 Asymmetric C-O-C stretching (urethane) 
q 900 Asymmetric ring stretching (cyclohexane) 
r 779 Cyclohexane ring breating 
 
 
   
Figure 48: FTIR spectra of ZnO/PU composite DDSs with 25 wt% ZnO content 
 
As was observed in the FTIR spectra for the ZnO powders, a strong absorption peak is 
partially seen in the experimental range near 400 cm-1 due to the Zn—O bond for the 
composite samples shown in figure 46. The peaks shown near 2900 cm-1 can be 
attributed to C—H bonds. The assortment of peaks between 1000 and 2000 cm-1 can be 
assigned by interactions between carbon, nitrogen, and oxygen atoms in the polyurethane 
component of the composites, which are specifically detailed in table 7. Similar to the 
powder spectra, a broad peak around 3500 cm-1 is observed due to O—H bonds of 
hydroxyl components for the composite samples.  
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Figure 49: FTIR spectra of 50 wt% ZnO/PU composite DDS showing spectra of both pure ZnO and PU 
 
Referring to figure 47 enables comparison of the spectra between the composite DDS and 
its individual components (pure PU and pure ZnO). The black line, showing the data for 
the composite sample, shows no deviation in terms of peak positions compared to the red 
(PU) and blue (ZnO) lines. This suggests that there is little chemical interaction between 
the ZnO and PU, as no additional peaks arise in for the composite sample, nor do the 
peak positions shift in the composite sample from their positions in the spectra of the 
individual components.   
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4.3. Drug Release Studies 
 
 
4.3.1. Variations in Drug Loading Concentration 
 
 
Figure 50: Drug release curves for nanostructured ZnO loaded with different amounts of IBU. IBU 
loading was performed by soaking ZnO in ethanolic solutions of IBU with different IBU concentrations 
(mg of IBU/ml of ethanol). 
 
Drug release studies were completed to investigate various influences based on variation 
preparation methods of different DDSs. In the first investigation, the powders were loaded 
in ethanol solutions containing different concentrations of ibuprofen (1, 2, 10, and 20 
mg/mL). It can be seen in figure 48 that an increase in loading concentration corresponds 
to an increase in the relative amount of drug released. This means that the drug uptake 
was higher for samples loaded in solutions of higher ibuprofen concentration, as one 
would expect. In applications where dosage is an important parameter for a drug delivery 
system, it is useful to be able to control the amount of drug stored in the DDS. The results 
from this study show that it is possible to control the drug uptake during the loading 
procedure simply by adjusting the drug concentration in the loading solution.  
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However, it should be noted from the figure that doubling the loading concentration does 
not result in a doubling of the maximum amount of drug released. In fact, changing the 
loading concentration from 1 to 2 mg/mL has only a small effect in the maximum drug 
released. Similarly, a tenfold increase in concentration from 1 to 10 mg/mL results in 
slightly more than double the amount of drug released.  
 
Comparing the relative shape of the release profiles reveals a consistency in the generic 
behavior of the drug release systems. Namely, an initial burst release occurs over the first 
24 hours followed by a slower release stage that continued over the course of the study. 
Additionally, the slope of this second stage is quite comparable between the studies. This 
could suggest that a certain amount of drug is strongly connected to the ZnO surface 
which is slowly released over a long time period and that the increase in loading 
concentration provides additionally loosely bound ibuprofen, which can be observed by 
the increase in the amount of drug released in the initial burst stage. 
 
 
4.3.2. Influence of Post-Loading Washing Procedure 
 
 
 
Figure 51: Drug release curves for nanostructured ZnO showing the effect of washing post-loading 
Chapter 4 – Results and Discussion 
 
84 
 
 
The second study on drug loading was complete in order to investigate the effect of 
washing the samples after loading in ethanol with an ibuprofen concentration of 10 
mg/mL. This was completed as the procedure described in literature is often unclear and 
no standard practice as to handling the loaded powder exists; some papers report 
washing the samples while others forego a washing procedure. For this study, the 
samples were washed through centrifugation.  
 
It can be seen in figure 49 that the washing procedure has a detrimental effect on the 
maximum amount of drug released. Namely, after the first wash cycle, the maximum drug 
released and thus the drug present in the carrier dropped nearly in half. However, after the 
third wash cycle the relative amount of drug released remained consistent. This suggests 
that a loosely bound layer of ibuprofen exists on the loaded sample that is easily removed 
during the first wash cycle. Then, the remaining drug is strongly enough bound so that its 
removal is not induced by subsequent wash cycles.  
 
 
Figure 52: SEM Images of samples loaded in ethanol with IBU concentration of 10 mg/mL. Top row: 
particles with no post-loading wash cycles; second row: particles with 1 post-loading wash cycle; row 
3: particles with 3 post-loading wash cycles 
 
Chapter 4 – Results and Discussion 
 
85 
 
The effects of the washing cycles on the particle morphologies are shown in figure 50, 
which depicts SEM images of the three samples at various magnifications. For each 
sample, two particles are shown in order to demonstrate the consistency of the washing 
effect on the particles. It can be seen that the washing cycles affect the particle surface 
structure. Where the unwashed sample can be characterized by the typical assembly of 
distinct nanoplatelets, the surface of the washed particles is much smoother. In the 
images at magnification of x10000, the nanostructure of the washed particles can barely 
be distinguished. Because of this effect on the structure of the particles themselves, it can 
be easily imagined that the washing procedure removes the loosely attached ibuprofen. 
 
Practical implications of these results are clear, which can be understood by the fact that 
additional procedural steps in the creation of a DDS can impact the drug release profile of 
the system. Here it has been seen that washing the samples after loading unsurprisingly 
reduces the amount of drug released from the system due to removal of the adsorbed 
drug molecules during the wash procedure. Whether a washing procedure can be 
recommended for use or not is largely dependent on the application in mind with respect 
to the intended dosage. However, as common DDS applications typically benefit from 
larger loading capacities, it would be recommendable that the washing step is eliminated 
from DDS production procedures. 
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4.3.3. Drug Release from Composite Delivery Systems 
 
 
 
Figure 53: Drug release curves comparing powder to composite DDS 
 
The final study examined the drug release from the composite DDSs. These samples 
were prepared from unwashed ZnO powders that were loaded in ethanol with ibuprofen 
concentrations of 10 mg/mL. Figure 51 illustrates the typical behavior of the composite 
system as compared to the powder systems. It can be seen by comparison to figure 48 
that the drug release depicted for the composite samples in figure 52 shows a maximum 
release that is lower than that corresponding to the ZnO powder DDS, due to the diffusion 
barrier presented by the polymeric material. The burst-effect can also be observed for the 
composite samples, suggesting the presence of a large amount of loosely bound drug 
molecules. 
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Figure 54: Drug release curves for ZnO/PU composite drug delivery systems 
 
A comparison of the release profiles for the two produced composite systems (25 and 50 
wt%) is shown in figure 52. Upon initial interpretation, the results might seem contrary to 
the expectation that the 50 wt% should have a larger amount of drug released as the 
larger proportion of PU in the 25 wt% would suggest the presence of longer diffusion 
pathways for the drug during release. However, a few observations can be made to 
explain this seemingly contradictory result. Firstly, the y-axis of the graph is given in 
reference to the amount of ibuprofen released relative to the weight of ZnO in the 
composite. In terms of IBU loading with respect to the weight of the composite, the 50 wt% 
is higher and the drug release in terms of mg IBU/mg composite is higher for this sample. 
Though, this does not explain the fact that figure 52 shows the 25 wt% sample to release 
a higher percentage of the loaded IBU. As was mentioned previously, it was observed in 
the solvent evaporation process that the loaded ZnO powder tended to settle in the 
mixture with PU so that the final composites would not be characterized by an even 
distribution of powder across the height of the cylindrical samples. For the 25 wt% sample, 
a larger proportion of the powder was located towards the bottom surface of the 
composite, which would be associated by short diffusion pathways for the IBU to release 
from the DDS. Although the 25 wt% composite had more polymer to serve as hindrance to 
IBU diffusion, the system was not arranged in a way for the PU to serve its expected 
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purpose. Thus, a higher percentage of the drug could be released during the experiment. 
For the 50 wt% sample, on the other hand, a larger percentage of the loaded powder was 
located within the bulk of the sample, where the drug diffusion would be have the longest 
pathway. 
 
4.3.4. Modeling of Release Curves 
 
Assigning proposed mathematical models to the drug release curves was done in order to 
better predict the properties of drug release for the DDSs. Figure 53 shows the fitting of 
the different models to the IBU release profile corresponding to the sample loaded at 10 
mg/mL. Five models have been selected in an attempt to match the data to established 
models, which have been presented in the introduction: first order, Higuchi, Korsmayer-
Peppas, Baker-Lonsdale, and Makoid-Banaker.  
 
It can be seen that the Korsmeyer-Peppas model as well as the Makoid-Banaker model fit 
the data quite well. The Korsmeyer-Peppas model was selected as the best fit to the drug 
releases of this study based on the combination of a good fit to the data and its simplicity. 
The Korsmeyer-Peppas model is given by the equation:  
 𝐹 = 𝑘!"𝑡! 
 
where kKP and n are constants. This model is quite similar to that given by the Higuchi 
model. However, for the Higuchi model, the power is given by a constant as opposed to 
being restricted to 0.5. To reiterate from the introduction, this model was designed for 
polymeric DDSs to account for simultaneous drug release and swelling due to water 
absorption. For this reason, it is surprising that the model fits well to the data, as the drug 
was loaded into inorganic nanostructured particles. Thus, while the equation can generally 
fits the data, as seen in figure 53 and 54, it should be taken as an empirical fit as opposed 
to drawing conclusions to the physical properties of the material based on the constants in 
the equation. In other words, as the system under study (loaded ZnO particles) does not 
fall under the realm of intended use for the Korsmeyer-Peppas model, one should be 
careful to infer significant meaning from the constants.  
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Figure 55: Release curve for nanostructured ZnO loaded at 10 mg/mL and selected models 
 
In a similar light, the Higuchi model, while commonly used in DDS studies, fails to 
accurately represent the present data. Here, however, it is rather expected to see 
shortcomings in the fitting ability of the Higuchi model, as its intention was to model the 
diffusion of drug out of a thin film matrix, such as an ointment.  
 
Closely mirroring the Higuchi model, the Baker-Lonsdale model, shown as the purple line 
in figure 53, also fails to accurately represent the experimental data. This is disappointing, 
as the model offered the most promise with regards to describing the drug release based 
on physical properties of the system, such as diffusion coefficient of the drug, drug loading 
concentration, and size of the carrier. Had it more closely modeled the data, it could have 
been used as another measure to estimate a quantitative value for the ibuprofen drug 
loading.  
 
The Makoid-Banaker model fits the data set nicely, however this is an unsurprising result 
due to the inclusion of three empirical constants in the model. To restate from the 
introduction, the model includes both power and exponential relationships with time, each 
including their own empirical constant. In this way, the Makoid-Banaker model can be 
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applied to an array of drug release profiles. However, it offers little insight into the release 
mechanisms.  
 
Lastly, the first order model, while not perfectly fitting the data, can be seen to closely 
approximate the release profile. This suggests that the drug release occurs through a 
Fickian diffusion process, where a large concentration gradient exists between the 
nanostructured ZnO particles and the PBS release medium. 
 
  
  
   
Figure 56: Korsmeyer-Peppas model applied to various drug releases of nanostructured ZnO loaded 
with IBU. A: 1 mg/mL; B: 2 mg/mL; C: 10 mg/mL; D: 20 mg/mL; E: 10 mg/mL 1 wash; F: 10 mg/mL 3 
wash 
 
 
A) B) 
C) D) 
E) F) 
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4.4 Degradation of the Drug Delivery Systems 
 
 
SEM images were created to look at the microstructure of the DDSs before and after the 
drug release in order to gain insight into possible release mechanisms. These are shown 
in figure 55 for the nanostructured ZnO particles and figure 56 for the composite drug 
delivery systems. 
 
 
4.4.1 Degradation of Nanostructured ZnO 
 
 
   
Figure 57: SEM of nanostructured ZnO before (left) and after (right) being subjected to shaking at 125 
rpm in PBS at 37 °C for 14 days during a drug release experiment 
 
Comparison of the left and right sections of figure 45, showing the nanostructured ZnO 
before and after the drug release experiments, respectively, shows that the structural 
integrity of the particles is maintained, even after being subjected to shaking at 125 rpm in 
PBS for 2 weeks. It can be seen that the particles post-release can still be characterized 
by an agglomeration of nanoplatelets that form spherical particles of roughly 4 microns in 
diameter. This observation suggests that the drug release occurs primarily by desorption 
of the drug from the particle surface, and that other mechanisms based on the particle 
degradation do not occur. 
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4.4.2 Degradation of ZnO/PU Composites 
 
 
 
Figure 58: SEM image of ZnO/PU composite DDSs before and after being subjected to drug release 
medium for 16 days 
 
Similar to the situation of the ZnO particle degradation (or lack thereof), the ZnO/PU 
composites also withstand the drug release environment. As documented in figure 56, the 
images taken before and after the drug release experiments are nearly indistinguishable 
from each other. This suggests that the composites are physically robust, and do not 
easily degrade in solutions with high salt concentration (e.g. PBS). This offers practical 
significance in applications for where the structure of the DDS should be maintained, as 
would be useful for bone or vascular implants. Furthermore, this observation offers insight 
into the drug release mechanisms. Namely, the polymer plays little role in the drug release 
process aside from serving as a diffusion barrier. As no swelling or degradation of the 
system was observed, it is indicative that, even in the more complex composite system, 
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the drug release occurs through desorption from the ZnO particles and diffusion 
throughout the composite into the release medium. 
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5. Conclusions and Future Work 
 
In this work, drug delivery systems based on nanostructured zinc oxide as well as 
composite DDSs based on nanostructured zinc oxide embedded in polymeric matrices of 
polyurethane were successfully created. It has been shown that the chemical precipitation 
of the nanostructured ZnO powders allows particles to form with uniform morphologies 
and narrow size distributions as well as providing a simple and repeatable method for 
synthesizing an oxide material without the need of high temperatures for calcination 
processes.  
 
Various characterization techniques have been used on both loaded and unloaded 
samples of the zinc oxide powders in order to examine the role of loaded ibuprofen. It was 
confirmed that it is possible to control the drug loading in the samples by controlling the 
ibuprofen concentration in the loading solutions. It was also found that washing the 
samples post loading resulted in a decrease in the amount of drug loaded, likely caused 
by the removal of a loosely bound layer of ibuprofen. An associated smoothing of the 
particle surfaces was observed for the washed samples. 
 
Finally, the composite samples were able to reduce the drug release by providing barriers 
to the diffusion of ibuprofen out of the zinc oxide nanostructures. In both systems (particle 
and composite DDSs), subjecting the carriers to the release medium had little effect on the 
overall structural integrity of the samples. No degradation was observed.  
 
Suggestions for future work would be to further investigate the role of variations in drug 
loading and how composites created with powders of different loadings behave. 
Experiments performed in release media of various acidities would also be interesting and 
could provide information pertaining to the material’s use in response-driven drug release. 
Additionally, it would be desirable to develop a method to accurately and quantitavely 
determine the amount of ibuprofen loading in the samples so a relationship could be 
develop between the concentration in the loading solution and drug release potential.  
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Appendix 
 
Table 8: R2 values for the various mathematical models 
Sample First Order Higuchi Korsmeyer-Peppas 
Baker-
Lonsdale 
Mankoid-
Banaker 
1 mg/mL .75 .90 .93 .92 .97 
2 mg/mL .59 .52 .93 .09 .96 
10 mg/mL .87 -.51 .73 .32 .76 
20 mg/mL .88 .07 .92 .80 .95 
1 Wash .57 -2.8 .63 .24 .72 
3 Washes .73 -2.8 .66 .30 .71 
 
 
 
 
 
 
 
